隨著歐洲與東南亞吸納越來越多國際護理人員,全球護理人員遷徙模式正發生轉變

賓夕法尼亞州費城, 2026年4月28日 - (亞太商訊 via SeaPRwire.com) - TruMerit™(前身為 CGFNS International)今日發布《2025年護理人員遷移報告》,揭示全球護理人員遷移模式出現顯著變化,且在醫療保健需求差異極大的各區域間,護理人力分布的不平等現象正日益加劇。該報告透過分析世界衛生組織的數據及 TruMerit 專有的 VisaScreen® 申請紀錄,顯示國際護理人員的流動正日益集中於醫療基礎設施較完善的地區,而面臨嚴重護理人力短缺的地區,在僱用國際教育背景護理人員的能力方面則持續處於劣勢。歐洲與東南亞地區的國際護理師僱用量呈現急遽增長。根據TruMerit對世衛組織護理人力數據的分析,歐洲目前僱用的國際教育背景護理師比例已達其醫療保健人力總數的8.01%,相較於過去十年的平均值5.96%,呈現出持續且顯著的上升趨勢。東南亞地區的國際護理人員佔醫療人力比例最高達24.87%,相較於過去十年的平均值20.15%——儘管過去十年間存在波動,這再次顯示出顯著且穩定的趨勢。同期,東地中海及非洲地區的國際護理人員比例則有所下降,加劇了醫療資源不足地區現有的護理人力短缺問題。「這些數據揭露了日益加劇的全球失衡現象:資源充沛的醫療體系正加速吸納海外受訓的護理人員,而護理人力短缺最嚴重的地區卻正失去僱用這些他們急需的專業人才的能力,」TruMerit 總裁兼執行長彼得·普雷佐西(Peter Preziosi)博士表示。「要糾正這種資源分配失衡,源頭國與目的地國必須採取協調行動——這需以符合倫理的招募框架為基礎,透過更強有力的雙邊協議來協助抵銷源頭國所承擔的教育與培訓成本,並持續投資於醫療資源匱乏地區的護理教育及醫療體系能力。」國際護理師職涯路徑日益複雜該報告強調了國際護理師流動性日益增加的現象。TruMerit對2021至2024年VisaScreen資格認證數據的分析顯示,約3%移居美國的護理師在申請美國執業許可前,已曾在其他國家工作過——這顯示全球護理勞動力正變得日益流動,多次跨國職涯轉移已日趨普遍。「本報告的數據清楚顯示,護理人員的流動不僅僅是供需問題——它反映出全球醫療教育、就業容量及醫療資源分配方面更深層的結構性不平等,」TruMerit 全球事務總監羅德里戈·戈維亞(Rodrigo Gouveia)表示。「建立協調的政策框架、投資護理教育體系,以及強化醫療資源匱乏地區的醫療基礎設施,對於確保國際護理人員流動能促進而非加劇全球健康公平至關重要。」新興風險:AI 生成之執照造假威脅護理人力資源的完整性《2025 年護理人員遷徙報告》亦探討了威脅醫療人力資源完整性的新興風險,包括預計將增加的 AI 生成職業詐欺。產業分析師預測,到 2026 年,每四份求職者履歷中就有一份可能是由人工智慧偽造的,這凸顯了經核實的護理執照認證系統對於保障患者安全的重要性日益增加。完整的《2025年護理人員遷徙報告》可於此處下載。關於 TruMeritTruMerit 是全球醫療人力資源發展的領導者,擁有近 50 年協助護理人員及其他醫療工作者實現職涯流動的經驗。TruMerit 前身為 CGFNS International,專門為尋求在美國及其他國家執業許可的海外醫療專業人員,驗證其教育背景、培訓經歷及專業經驗。透過其擴展的使命及「全球醫療人力發展研究院」,TruMerit 致力推動研究、標準制定與認證工作,以強化全球醫療人力資源,並促進公平且可持續的職業流動。媒體聯絡人LEA SIMS行銷與傳播總監TruMeritmedia@trumerit.org消息來源:TruMerit Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Global Nurse Migration Patterns Shift as Europe, Southeast Asia Absorb Growing Share of International Nurses

PHILADELPHIA, PA, Apr 28, 2026 - (ACN Newswire via SeaPRwire.com) - TruMerit™ (formerly CGFNS International) today released its 2025 Nurse Migration Report, revealing significant shifts in global nurse migration patterns and widening inequities in nursing workforce distribution across regions with vastly different healthcare needs.The report, which analyzes World Health Organization data and TruMerit's proprietary VisaScreen® application records, shows that international nurse migration flows are increasingly concentrated in regions with stronger healthcare infrastructure, while areas facing severe nursing shortages continue to lose ground in their ability to employ internationally educated nurses.Europe and Southeast Asia see sharp increases in international nurse employment. According to TruMerit's analysis of WHO nursing workforce data, Europe now employs internationally educated nurses at a rate representing 8.01% of its healthcare workforce, compared to a ten-year average of 5.96%-a persistent and significant upward trend. Southeast Asia has seen internationally educated nurses as high as 24.87% of the healthcare workforce, compared to a ten-year average of 20.15%-again, indicative of a notable, steady trend despite fluctuations over the past decade. During the same period, the proportion of internationally educated nurses working in the Eastern Mediterranean and African regions has declined, exacerbating existing nursing shortages in underserved areas."These data expose a widening global imbalance: well-resourced health systems are accelerating their absorption of internationally educated nurses, while regions with the most severe nursing shortages are losing the capacity to employ the very professionals they urgently need," said Dr. Peter Preziosi, President and CEO of TruMerit. "Correcting this maldistribution will require coordinated action by both source and destination countries--grounded in ethical recruitment frameworks, stronger bilateral agreements that help offset the education and training costs borne by source countries, and sustained investment in nursing education and health system capacity in underserved regions."Growing Complexity of International Nurse Career PathwaysThe report highlights increasing mobility among internationally educated nurses. TruMerit's analysis of VisaScreen credentialing data from 2021-2024 shows that approximately 3% of nurses migrating to the United States had already worked internationally in another country before applying for U.S. authorization-evidence of an increasingly mobile global nursing workforce in which multiple international career moves are becoming more common."The data in this report make clear that nurse migration is not simply a matter of supply and demand-it reflects deeper structural inequities in how healthcare education, employment capacity, and healthcare resources are distributed globally," said Rodrigo Gouveia, Chief Global Affairs Officer at TruMerit. "Coordinated policy frameworks, investment in nursing education systems, and strengthening of health infrastructure in underserved regions are essential to ensuring that international nurse migration supports rather than exacerbates global health equity."Emerging Risks: AI-Generated Credential Fraud Threatens Nursing Workforce IntegrityThe 2025 Nurse Migration Report also examines emerging risks to healthcare workforce integrity, including the projected rise in AI-generated occupational fraud. Industry analysts project that by 2026, one in four job candidate profiles may be fabricated by artificial intelligence, underscoring the increasing importance of verified nurse credentialing systems for protecting patient safety.The full 2025 Nurse Migration Report is available for download here.About TruMeritTruMerit is a worldwide leader in healthcare workforce development with nearly 50 years of experience supporting the mobility of nurses and other healthcare workers. Formerly CGFNS International, TruMerit validates the education, training, and professional experience of internationally educated health professionals seeking authorization to practice in the United States and other countries. Through its expanded mission and the Global Health Workforce Development Institute, TruMerit advances research, standards, and certifications that strengthen the global health workforce and promote equitable, sustainable career mobility.Media ContactLEA SIMSChief Marketing & Communications OfficerTruMeritmedia@trumerit.orgSOURCE: TruMerit Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Tenstorrent Enables AI At Scale with Industry-Leading Performance Deployed on Novel Networked AI Architecture

SANTA CLARA, CA, Apr 28, 2026 - (ACN Newswire via SeaPRwire.com) - Tenstorrent, the AI compute company led by CEO, Jim Keller, announces today general availability of Tenstorrent Galaxy Blackhole deployed at scale, delivering industry-leading general-purpose AI performance. Other solutions require bolting together separate accelerators across fragmented infrastructure. Tenstorrent's Networked AI delivers them natively - compute, memory, and networking unified into a single system optimized for real-world AI workloads.Leading Industry Performance, Affordable PricesGeneral-purpose means leading performance on every workload defining modern AI, not specializing in one. Tenstorrent Galaxy tops video generation, large-context LLM inference in both prefill and decode, and the full range of model architectures shipping today.See it for yourself on Friday, May 1st at 1:30pm PT at Tenstorrent's launch event, TT-Deploy. Watch the livestream: https://tenstorrent.com/deploy10x Faster Real-time High-quality AI Video GenerationAI Video Generation on Tenstorrent Galaxy is 10x faster than leading GPU systems. In collaboration with Prodia, the industry's fastest video generation is now 10x faster running on a Tenstorrent Galaxy supercluster and generating 720p, 81-frame video in brisk 2.4 seconds. Run state-of-the-art video models and generate high quality videos faster on Tenstorrent Galaxy superclusters."We were already leading the Artificial Analysis leaderboard, and working with Tenstorrent allowed us to unlock another 10x improvement in video generation speed. The integration was seamless, and the performance gains were immediate." Mikhail Avady and Monty Anderson said, co-founders of Prodia Labs.Blitz Mode: Fastest and Largest-Context LLM InferenceBlitz Mode on Tenstorrent Galaxy, optimized for premium, latency-sensitive AI workloads, enables 350+ t/s/u and sub-4-second time-to-first-token on Deepseek-R1-0528 671B, beating the leading comparable GPU systems. Tenstorrent Galaxy superclusters run high margin AI use cases including agentic workflows, real-time systems, and long-context reasoning.Tenstorrent Galaxy Performance BenchmarksDecode: DeepSeek-R1-0528 671B up to 350+ tokens/second/user -- faster than the fastest inference systems from Groq and Cerebras in performance and capacity supporting batch sizes from 8 to 64 and up to 128k contextPrefill: DeepSeek-R1-0528 671B sub-4-second time-to-first-token on 100K context -- running on the same general-purpose AI Tenstorrent Galaxy superclustersFull-Stack AI, Ready for ProductionTenstorrent provides a complete AI solution - from hardware to software to deployment. Tenstorrent Galaxy integrates with open-source frameworks through TT-ForgeTM and TT-Lang, and supports rapid model bring-up, enabling customers to deploy production AI systems without vendor lock-in or proprietary stacks. 90% of models from HuggingFace just work on Tenstorrent hardware.Networked AIThese results are enabled by an architecture built around a different constraint. Most AI accelerators treat compute as the primary design problem. Tenstorrent instead solved data placement and data flow first which enables performance through scaling."Every company in the industry is pairing up to build the accelerator accelerator accelerator. CPUs run code. GPUs accelerate CPUs. TPUs accelerate GPUs. LPUs accelerate TPUs. And so on. This leads to complex solutions which are unlikely to be compatible with changes in AI models and uses. At Tenstorrent, we thought something more general and simpler would work," said Jim Keller, CEO of Tenstorrent.The result is what Tenstorrent calls Networked AI: a new model for AI infrastructure where compute, memory, and networking are unified into a single system optimized for real-world AI workloads. By combining efficient data placement and data flow, high bandwidth on-chip memory, and Ethernet-based scale-out, the architecture scales from a single core to thousands of servers under one software model, without proprietary interconnects, without reconfiguration, and without the rigid workload declarations that make competing systems brittle as models evolve.DeploymentsTenstorrent Galaxy superclusters are one of the new foundations of Equinix's Distributed AI HubTM, a full-stack AI orchestration platform for agentic workloads, launching today with partners BetterBrain and OrionVM. Equinix's Distributed AI Hub helps customers and partners cover every layer from infrastructure to application, and plugs into legacy enterprise systems, enabling customers to deploy, and operate, sovereign agentic AI systems.Equinix: A global digital infrastructure company that provides colocation and interconnection services, enabling enterprises and partners to deploy and scale AI - along with other mission-critical workloads - securely, efficiently, and in close proximity to users, clouds, and data.OrionVM: Next-gen heterogeneous cloud platform partner powering the orchestration and infrastructure layer for Tenstorrent-based AI services.BetterBrain: A full-stack AI platform and deployment partner delivering secure, customizable, production-ready AI applications and agentic workflows on Tenstorrent infrastructure."Tenstorrent brings immense value to our Distributed AI Hub by fundamentally rethinking how AI workloads are executed-from optimizing data flow on-chip across prefill and decode, to orchestrating the full AI stack. This level of architectural intelligence allows enterprises to stay focused on building differentiated products, not managing infrastructure complexity," said Justen Aguillon, Director of Technology Partner Ecosystems."We're enabling a new class of AI factories-high-performance, cost-efficient environments with the flexibility to run both frontier and open-source models, and the embedded telemetry and governance required to scale agentic systems globally."Additional deployments announced today include:Virtu Financial, a tier-1 market maker working with Tenstorrent to enable real-world AI systems: on-premises agentic AI solutions for trading and operational automationTuriyam, a next-generation semiconductor and AI infrastructure company building datacenter-scale inference chips, software, and systems from India for the worldCirrascale, a top tier neocloud with cloud services for agentic applications and generative AI, available in the US and multiple international regionsai&, Japan's vertically integrated AI platform: the largest installation of Tenstorrent hardware to power AI infrastructure, models, and applications across Japan and around the world."We evaluate a lot of hardware. Most of it is incremental. Tenstorrent Galaxy Blackhole is not. Tenstorrent has taken a clean-sheet approach to AI infrastructure, and the results speak for themselves. Putting this in the hands of our customers is exactly the kind of move Cirrascale exists to make." said Dave Driggers, CEO and Co-Founder, Cirrascale Cloud Services.Run anything - Fast, Simple, Affordable - with Tenstorrent Galaxy Blackhole.Tenstorrent Galaxy Blackhole is Tenstorrent's air-cooled compute server built with Tenstorrent's next-generation Blackhole® chips and fully open-source software stack. Starting at $110,000, it delivers 23 PFLOPS Block FP8 of AI compute from 32 Blackhole chips, 6.2 GB of on-chip SRAM with 2.9 PB/s, 1 TB of DRAM with 16 TB/s, and up to 56 × 800G Ethernet ports for 11.2 GB/s of scale-out bandwidth. Tenstorrent Galaxy Blackhole systems scale seamlessly from a single server to multi-rack deployments using standard Ethernet networking. Customers deploy configurations ranging from 4 to 36 or more Tenstorrent Galaxy systems, optimized for workloads including AI video generation, large-scale LLM inference, and private AI infrastructure. Our base Tenstorrent Galaxy Blackhole supercluster of four Tenstorrent Galaxies starts at $440,000.About TenstorrentTenstorrent is an AI compute company led by CEO Jim Keller - architect of Apple A4/A5, AMD Zen, and Tesla's Full Self-Driving chip. The company builds RISC-V-based AI processors and systems for developers, enterprises, and sovereign infrastructure worldwide. In addition to servers and workstations, Tenstorrent licenses its Ascalon RISC-V CPU and Tensix AI cores to chip designers including Samsung and LG. Backed by Bezos Expeditions, Samsung, LG Electronics, Hyundai Motor Group, Fidelity, and others, Tenstorrent has raised over $1B+ and operates from Santa Clara, Austin, Toronto, Belgrade, Tokyo, and Bangalore.tenstorrent.comMedia Contact:Justin MauldinSalient PRachievemore@salientpr.com737.234.0936SOURCE: Tenstorrent Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HKTDC’s response to Hong Kong’s export figures for March

HONG KONG, Apr 28, 2026 - (ACN Newswire via SeaPRwire.com) - The Census and Statistics Department today released the latest external merchandise trade statistics. In March 2026, the total value of Hong Kong’s merchandise exports recorded a year-on-year increase of 35.8% to HK$618.4 billion. For the first quarter of 2026, the total value of exports of goods amounted to HK$1,546.2 billion, representing a robust growth of 32.0% compared with the same period last year.Commenting on the outlook, Bruce Pang, Director of Research at the Hong Kong Trade Development Council, said Hong Kong’s exports are expected to remain steady at least in the near term, despite elevated energy prices arising from ongoing tensions in the Middle East. He noted Hong Kong’s external trade has continued to exhibit clear growth momentum, underpinned primarily by sustained global demand for electronic items and other intermediate goods that are integral to regional and global supply chains.In particular, resilient input demand from the Chinese Mainland and other ASEAN production sites, together with stable demand from major overseas markets, has provided a solid buffer against external headwinds. While geopolitical uncertainties persist and energy prices are likely to remain relatively high, continued industrial activity in major markets, as well as ongoing supply-chain realignments, are expected to lend ongoing support to Hong Kong’s trade flows.“Overall, we maintain a cautiously optimistic outlook for Hong Kong’s trade performance, while remaining mindful of potential volatility arising from geopolitical developments and cost pressures,” Pang added.HKTDC Media Room: https://mediaroom.hktdc.com/enMedia enquiriesPlease contact the HKTDC’s Communications & Public Affairs Department:Jane CheungTel: (852) 2584 4137Email: jane.mh.cheung@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) celebrates its 60th anniversary this year. The HKTDC is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus.  Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

CanSinoBIO Delivers Q1 Revenue Growth Amid Accelerating International Expansion

HONG KONG, Apr 28, 2026 - (ACN Newswire via SeaPRwire.com) - CanSino Biologics Inc. (688185.SH/06185.HK) released its first-quarter 2026 results, reflecting a positive operational momentum. Revenue for the quarter totaled RMB 190 million, representing a 38.73% year-over-year increase.The performance highlights the company’s strong operational resilience, driven by accelerating sales of core products and ongoing cost-efficiency measures. Despite short-term pressure on profitability, steady revenue expansion sets a solid foundation for a full-year earnings recovery.Menhycia(R), the first MCV4 vaccine product in China, maintained robust sales during the period. The successful launch of iPneucia(R) (13-valent pneumococcal polysaccharide conjugate vaccine) also contributed considerable revenue to the Group. Meanwhile, international technology transfer and intermediate products sales have gradually emerged as new revenue growth drivers.CanSinoBIO has developed a differentiated portfolio of bacterial vaccines, covering meningococcal, pneumococcal and DTcP vaccines. The company leverages five core technology platforms, including viral vector vaccines, synthetic vaccines, protein structure design and Virus-Like Particle (VLP) assembly, mRNA technologies, and formulation and delivery systems. This diversified pipeline helps mitigate the “single-product dependency” that has historically challenged traditional vaccine manufacturers.Among its key products, Menhycia(R), China’s first domestically developed quadrivalent meningococcal conjugate vaccine, has continued to gain market traction following approval for expanded use in children up to six years old, driving steady gains in market penetration. Meanwhile, iPneucia(R), China’s first 13-valent pneumococcal conjugate vaccine using a dual-carrier system (CRM197 and tetanus toxoid), has ramped up since launch and emerged as a key growth driver.In April, the company also received approval for Tripecia(R), an adsorbed acellular pertussis (three-component) combination vaccine (DTcP) for infants. Leveraging next-generation technology, the product fills a gap in the domestic market and further strengthens CanSinoBIO’s presence in the pediatric segment.Beyond the infant market, CanSinoBIO is advancing a “life-course immunization (from infancy through old age)” strategy, expanding into adolescent and adult vaccines. Pipeline candidates, including adolescent and adult component Tdap vaccines (Tdcp) and a 24-valent pneumococcal conjugate vaccine, are progressing through development and clinical trials, aimed at broadening the company’s addressable market.On the international front, the company continues to pursue a dual-engine strategy of innovation and global expansion, transitioning from product exports to a more integrated global model. Menhycia(R) has been launched and supplied in Indonesia, while manufacturing facilities for both Menhycia(R) and iPneucia(R) have obtained PIC/S GMP certification from Malaysia. This integrated approach, spanning product registration, localized manufacturing and technology transfer, is expected to unlock significant opportunities in overseas markets.Looking ahead, with the continued ramp-up of core products and the gradual commercialization of its life-course vaccine pipeline, CanSinoBIO’s long-term value proposition may be poised for a re-rating, supported by both earnings’ growth and an expanding global footprint. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

康希諾生物一季度業績穩健增長 全生命週期佈局打開長期價值空間

香港, 2026年4月28日 - (亞太商訊 via SeaPRwire.com) - 康希諾生物(688185.SH/06185.HK)4月28日發佈2026年第一季度財報。報告顯示,公司一季度實現營業收入1.90億元人民幣,同比增長38.73%,彰顯了公司在核心產品放量與降本增效策略下的強勁經營韌性。儘管短期利潤承壓,但營業收入的穩健增長仍為全年業績修復奠定了堅實基礎。具體來看,曼海欣®作為中國首款四價流腦結合疫苗,銷售收入保持同期較高水平;13價肺炎球菌多糖結合疫苗優佩欣®的成功上市亦為本集團貢獻了可觀收入;同時,國際技術轉移及中間品銷售業務正逐步成為本集團新的收入增長點。作為國內領先的創新細菌性疫苗企業,康希諾生物依託病毒載體疫苗、合成疫苗、蛋白結構設計與VLP組裝、mRNA疫苗以及製劑與給藥技術五大核心技術平台,已構建起覆蓋腦膜炎、肺炎、百白破等多領域的差異化產品矩陣,有效破解了傳統疫苗企業面臨的「單品依賴」難題。整體而言,中國首款四價流腦結合疫苗曼海欣®(MCV4)在獲批擴齡至6週歲後,市場滲透率持續提升,繼續保持穩健增長;國內首款採用CRM197+TT雙載體蛋白技術的13價肺炎結合疫苗優佩欣®(PCV13i)上市後快速放量,已成為業績增長的新引擎。此外,公司於2026年4月剛剛獲批的嬰幼兒用吸附無細胞百(三組分)白破聯合疫苗盼康欣®,憑藉技術代際優勢填補了國內市場空白,進一步完善了公司在嬰幼兒疫苗領域的佈局。值得一提的是,公司正積極踐行「全生命週期免疫」理念,加速推進青少年及成人用組分百白破疫苗Tdcp、24價肺炎球菌多糖結合疫苗等管線的研發與臨床進程,旨在將產品線延伸至成人市場,從而打破單一細分市場的天花板限制。在國際化戰略上,公司堅持「創新+全球市場」雙輪驅動,加速從「產品出海」向「體系出海」升級。目前,曼海欣®已在印尼實現首發上市並啟動供應,曼海欣®和優佩欣®生產基地也獲得馬來西亞PIC/S GMP認證。這種涵蓋產品註冊、本地化生產到技術轉移的全方位出海模式,將為公司打開廣闊的海外市場空間。展望未來,隨著核心產品的持續放量以及全生命週期產品管線的逐步兌現,康希諾生物的長期價值有望在業績增長與全球化佈局的雙重驅動下迎來重估。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

The Prestigious U.S. Open Polo Championship(R) Final Closes a Record-Breaking American Polo Season, Supported by U.S. Polo Assn. and ESPN

West Palm Beach, FL, Apr 28, 2026 - (ACN Newswire via SeaPRwire.com) - U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), capped the American polo season with a thrilling finale as the 2026 U.S. Open Polo Championship® Final took center stage on April 26 at the USPA National Polo Center in Palm Beach County, Florida. Played on the iconic U.S. Polo Assn. Stadium Field, the most prestigious tournament in American polo, delivered elite international competition, worldwide broadcast exposure on ESPN, and an exciting Championship Sunday experience that resonated both on and off the field before a record crowd.U.S. Open Polo Championship Trophy with Team Pilot (L to R; Patron Curtis Pilot, Mackenzie Weisz, Camilo ‘Jeta' Castagnola, Lorenzo Chavanne)Pilot's Camilo ‘Jeta' Castagnola Scoring the Final Goal of the U.S. Open Polo Championship Final, Securing Pilot's Victory with a Score of 15-10Bob Bryan (R), One of the Greatest Doubles Tennis Players of All Time, Alongside USPA National Polo Center Tennis Professional Scott Williams (L), Conducting the Ceremonial Pre-Game Coin Toss at the U.S. Open Polo Championship FinalNashville Country Artist Abbey Cone Singing the National Anthem to a Record-Breaking Crowd for the U.S. Open Polo Championship Final at the USPA National Polo CenterBTA Mounted and Ready to Compete Against Pilot in the Prestigious U.S. Open Polo Championship Final U.S. Polo Assn. Models at the USPA Shop at NPC for the U.S. Open Polo Championship FinalPhoto Credit: Agustina FondaThe third and final chapter of the three-tournament Gauntlet of Polo® series brought together 11 top teams and many of the sport's most accomplished players, including 10-goal standouts Adolfo and Poroto Cambiaso, Hilario Ulloa, Tomas Panelo, and Jeta and Barto Castagnola. Other standout talents include Jesse Bray (7-goal), Lorenzo Chavanne (7-goal), Mackenzie Weisz (6-goal), Rufino Merlos (6-goal), Nico Escobar (6-goal), and Timmy Dutta (4-goal), to name a few. Rising stars and seasoned competitors alike, along with their equine partners, contributed to a highly competitive season that culminated in a Final that showcased something for everyone.To amplify the global reach of the event, the U.S. Open Polo Championship Final will once again be featured across ESPN platforms, with legendary commentator Chris Fowler hosting for the second consecutive year, alongside Kenny Rice, Polo Hall-of-Famer Adam Snow, and Karl Ude-Martinez. The broadcast, also available via Global Polo's YouTube, brings the excitement of the U.S. Open Polo Championship to a worldwide audience. Check local listings for airtimes.U.S. Open Polo Championship® Final at a Glance:Final Matchup: Pilot (#1 Curtis Pilot - 0, #2 Mackenzie Weisz - 6, #3 Lorenzo Chavanne - 7, #4 Camilo ‘Jeta' Castagnola - 10) vs. BTA (#1 KC Krueger - 1, #2 Steve Krueger - 5, #3 Tomas Panelo - 10, #4 Ignacio ‘Nachi' Viana -7)Date: April 26, 2026Location: USPA National Polo Center, Wellington, Florida, on the U.S. Polo Assn. Stadium FieldFinal Score: 15 (Pilot) - 10 (BTA)MVP: Lorenzo Chavanne (Pilot)Best Playing Pony: Open Texas, ridden by Lorenzo ChavanneBest Playing Pony, Argentinian Bred: Open Silaba, ridden by Lorenzo ChavanneU.S. Polo Assn. Sportsmanship Award, Presented by YETI: Steve Krueger (BTA)Skeeter Johnston - Sponsor of the Year: KC Krueger (BTA)Charity Beneficiaries: Polo Training Foundation (Pilot) and Museum of Polo & Hall of Fame (BTA)Broadcast: ESPN Platforms (Hosted by Chris Fowler with Kenny Rice, Adam Snow, and Karl Ude-Martinez), and Global Polo YouTubeGame Highlights: Pilot controlled the pace from the opening chukker, maintaining a strong multi-goal advantage that stretched to five goals midway through the third chukker. Despite the deficit, BTA regrouped at halftime and mounted an impressive push, narrowing the gap to a one-goal game in the second half. Pilot, however, never relinquished control, responding with precision to halt the momentum and rebuild their lead. In the final chukker, Pilot added two more goals to secure a 15-10 victory and back-to-back tournament wins following the USPA Gold Cup®. Lorenzo Chavanne and Camilo ‘Jeta' Castagnola led all scorers, each tallying seven goals in a standout offensive performance for the U.S. Open Polo Championship® Final.On Sunday, the BTA Team made history with its first-ever appearance in the U.S. Open Polo Championship® Final, featuring a husband-and-wife duo competing side by side. The game also marked a significant moment for the sport, with the BTA's female player making her U.S. Open Polo Championship debut, the first woman to make it to the Finals since Gillian Johnston won the U.S. Open Polo Championship in 2002, reflecting the sport's unique format where men and women play together on the field. Team Pilot entered the Final with strong momentum, seeking back-to-back major titles following their 2026 USPA Gold Cup victory.As the Official Sports Brand of the USPA, U.S. Polo Assn.'s presence was felt throughout the prestigious tournament, from outfitting teams with the brand's iconic Double Horsemen logo along with all NPC staff to creating immersive fan touchpoints across the venue. The sports brand also reinforced its commitment to the sport of polo and its community by making charitable donations to multiple polo and equine-based charities selected by finalist teams at all tournaments throughout the season."From a record-breaking season at the USPA National Polo Center to one of the most anticipated championship finals in the sport of polo, the U.S. Open Polo Championship® continues to raise the bar for our sport in the United States and around the world," said J. Michael Prince, President and CEO of USPA Global, the company that manages the multi-billion-dollar U.S. Polo Assn. brand. "Through U.S. Polo Assn.'s ongoing support and platforms like ESPN, we are able to bring the energy and tradition of this championship final to audiences around the world while continuing to create new fans and grow our sport and brand for future generations."Beyond the competition, Championship Sunday of the U.S. Open Polo Championship offered a vibrant, entertainment-driven atmosphere that resonated with longtime fans and new audiences alike. Tennis legend Bob Bryan of the Bryan Brothers delivered the ceremonial coin toss, while Nashville rising artist Abbey Cone performed the National Anthem. Guests enjoyed live music from Cone throughout the day, from pre-match moments at the Asado area to upbeat sounds during the traditional halftime divot stomp.U.S. Polo Assn. further elevated the on-site experience through curated retail and lifestyle activations at the USPA Shop at NPC, including a stunning polo artwork gallery featuring globally acclaimed equine artist Eduardo Marquez, the return of the interactive and eye-catching Briny Brim Custom Hat Bar, and complimentary chilled Limited Edition U.S. Polo Assn. rose served on the shop's porch, just beside the brand's polo ball photo wall for the perfect game day memory. Fans also took part in the iconic divot stomp tradition, receiving commemorative red, white, and blue caps in honor of the United States' 250th Anniversary.Established in 1904, the U.S. Open Polo Championship remains the definite test of excellence in American polo and a cornerstone of the international polo calendar, drawing the sport's top talent and passionate fans to Wellington, the Winter Equestrian Capital of the World, each season.B-Roll: https://f.io/lT0GXdwCAbout U.S. Polo Assn. and USPA GlobalU.S. Polo Assn. is the official sports brand of the United States Polo Association (USPA), the largest association of polo clubs and polo players in the United States, founded in 1890. With a multi-billion-dollar global footprint and worldwide distribution through more than 1,200 U.S. Polo Assn. retail stores as well as thousands of additional points of distribution, U.S. Polo Assn. offers apparel, accessories, and footwear for men, women, and children in more than 190 countries worldwide. The brand sponsors major polo events around the world, including the U.S. Open Polo Championship®, held annually at NPC in The Palm Beaches, the premier polo tournament in the United States. Historic deals with ESPN in the United States, TNT and Eurosport in Europe, Star Sports in India, and BeIn Sports in the Middle East now broadcast several of the premier polo championships in the world, sponsored by U.S. Polo Assn., making the thrilling sport accessible to millions of sports fans globally for the very first time.U.S. Polo Assn. has consistently been named one of the top global sports licensors in the world alongside the NFL, PGA Tour, and Formula 1, according to License Global. In addition, the sport-inspired brand is being recognized internationally with awards for global growth and sport content. Due to its tremendous success as a global brand, U.S. Polo Assn. has been featured in Forbes, Fortune, Modern Retail, and GQ as well as on Yahoo Finance and Bloomberg, among many other noteworthy media sources around the world. For more information, visit uspoloassnglobal.com and follow @uspoloassn.USPA Global is a subsidiary of the United States Polo Association (USPA) and manages the multi-billion-dollar sports brand, U.S. Polo Assn. USPA Global also manages the subsidiary, Global Polo, which is the worldwide leader in polo sport content. To learn more, visit globalpolo.com or Global Polo on YouTube.For Additional Information, Contact:Stacey Kovalsky - VP, Global PR and CommunicationsPhone +001.561.790.8036 - E-mail: skovalsky@uspagl.comShannon Stilson - VP, Sports Marketing and MediaPhone +001.561.227.6994 - E-mail: sstilson@uspagl.comSOURCE: U.S. Polo Assn. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Kincora Commences Drilling at the Historic Condobolin Mining Field

First phase drilling program underway at the 100% owned Condobolin epithermal gold, silver-base metals project located in the Cobar BasinCapital efficient sole funded drilling program of up to eight diamond core holes First systematic drilling in over a decade at the historic Condobolin Mineral Field Testing down dip, on strike, new adjacent coincident geochemical and geophysical targets at the high-grade Meritilga discovery Fully funded follow-up drilling proposed at Meritilga, with additional targets including other open prior discoveries and larger causative porphyry centers also under considerationRecent corporate activity highlights the value on high-grade projects in the Cobar BasinDrilling is ongoing in partnership with AngloGold Ashanti at the highly prospective Nevertire South porphyry project in the Macquarie ArcVancouver, British Columbia--(ACN Newswire via SeaPRwire.com - April 28, 2026) - Gold-copper explorer and hybrid project generator Kincora Copper Limited (ASX: KCC) (TSXV: KCC) (Kincora or the Company) is pleased to announce drilling has commenced at the Condobolin project, located in the southern end of the Cobar Basin in Central West NSW.John Holliday, Technical Committee chair, and Peter Leaman, VP of Exploration, commented,"We are very excited to be drilling at two highly prospective projects, including the first systematic drilling program in over a decade at our wholly owned Condobolin project. Our recent efforts have included consolidating the historic Condobolin mining field, an extensive airborne geophysical survey, a regional assessment of shallow historical workings, open prior explorer discoveries and potential causative porphyry targets.While water and the weathering profile previously impeded mining and exploration efforts those historic obstacles now support a compelling opportunity. The last phase of drilling delivered proof-of-concept with strong results and straightforward exploration upside at multiple historical mines and new discoveries, including a blind high-grade gold discovery at Meritilga. Cobar style deposits are often vertically extensive with repeating mineral systems. Our commenced program will, for the first time, properly test that potential at Mertiliga and advance our geological concept of a deeper intrusion(s) driving zoned hydrothermal systems across multiple historical mines and targets - offering both attractive grade and scale opportunity.Recent M&A in the Cobar district highlights the strategic value of high-grade precious and critical mineral deposits, particularly where synergies can be unlocked from existing processing capacity. The Condobolin project is an asset where a junior explorer like Kincora can add significant value." Figure 1: Kincora is currently sole-funding drilling at the Condobolin Mining Field while AngloGold Ashanti funds drilling (with Kincora receiving a management fee) at the Nevertire South license which is part of two earn-ins within the Northern Junee-Narromine Belt projectThe southern Cobar Basin remains relatively under-explored, with several recent discoveries in historic mining districtsTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/2305/294502_kincora_0427.jpgDistrict, regional and adjacent property information disclosed is provided for general awareness and educational purposes and is not necessarily indicative of any other project of the Company it is being compared to.ABOUT THE COBAR DISTRICTThe Cobar Basin has a 150-year history of high-grade, long-life mining and is an important supplier of critical and precious metals. The region benefits from established infrastructure and favourable ESG considerations with significant scope for processing and mining efficiencies, supporting further potential regional consolidation.The district has recently seen several significant new discoveries utilising modern exploration techniques in lesser explored regions (eg Federation, Achilles, Mallee Bull, Southern Nights and Wagga Tank) and emerging corporate activity (eg Harmony's A$1.6 billion takeover for MAC Copper (MAC.ASX), Aeris Resources A$214m acquisition of Peel Mining and Kingston Resources (KSN.ASX) recently receiving A$50 million cash for the first tranche of its divestment of its PNG Misima project).ABOUT THE CONDOBOLIN PROJECTThe Condobolin project was historically the focus of up to 25 informal open pit operations (peak late 1800's-early 1900's), with mining impacted by the water table and exploration by the weathering profile. The mineral field has not been effectively explored below the weathered zone (~30m).Very limited modern exploration has taken with initial activities by Clancy Exploration (Clancy, now RareX Limited) yielding encouraging results at all five prospects drilled (2011-13), including a virgin high-grade gold discovery at the Meritilga Prospect.More recently within the immediate district, Kingston Resources has significantly expanded the resources and restarted hard rock mining at the Mineral Hill mine, Talisman Mining has had success at its Rip N Tear and Durnings targets (to both the immediate north and south of Mineral Hill), while Australian Gold and Copper has excited the market with its new district scale discovery at its Achilles target located within the south western extension of the Cobar Basin.The Condobolin project is located approximately 40km south from the mill at Mineral Hill and north of the Condobolin town (which is the primary source of employees to Mineral Hill operation who drive through the Condobolin project to work) - see Figure 1.Kincora has consolidated a 100% project ownership and continued to expand our foothold across the near surface potential of the historical Condobolin Mineral Field. Approximately 20% of the wider project is out-sub cropping with the average depth of cover in non-outcropping areas less than 5 metres supporting very easy exploration with surface geology and sampling being an effective, quick and cheap methods.In 4Q'2025, the Company completed a ~150km2 airborne electro-magnetic (AEM) geophysical survey and the first systematic drilling program in over a decade commenced at the Meritilga target.Meritilga was a new blind shallow discovery made by Clancy in 2012 following up a coincident 2km x 2km arsenic-lead-zinc (+gold) geochemical anomaly and K-channel radiometric anomaly over ridges east of the historic mines at Mascotte and west of Potters. The anomalies coincided with key NE-striking structures identified in detailed 3D induced polarization (IP) surveys 1.The gold, silver and base metals system is situated within a lode with high grade lens (ore grade, eg 4m @ 20g/t gold, 30.2 g/t silver from 75m, including 1m @ 62g/t gold, 60g/t silver in hole CORC029) and a lower grade halo. The lode is a consistent body, open up and down dip 1, 2.Land access agreements are in place and the permitting process commenced for an up to 15 diamond drill hole program for 4100 metres testing down dip (up to 350m depth) and strike extensions and the potential for repeat high grade lens and/or a stacked series of lenses. Permits and land access are in place for a first phase program of up to eight holes.This setting is supported by the last phase of Reverse Circulation (RC) drilling by Clancy, the one diamond hole drilled by Kincora in 2023, coupled with a favourable structural setting where the main Meritilga Fault has been cross-cut by N-S trending faults 3.The program will also test new adjacent coincident geochemical and geophysical targets.The current working geological model, underpinned by pathfinder zonation and coincident geophysical anomalies, supports the potential for a larger mineralised intrusive source at depth, which this drilling program seeks to also support.ABOUT KINCORAKincora Copper Limited (ASX: KCC) (TSXV: KCC) is an emerging Australia-focused gold-copper explorer with a hybrid project generator strategy.The Company is successfully proving up the prospectivity of its extensive project portfolio, which includes multiple district-scale landholdings and scalable drill ready targets. These assets are located in Australia's Lachlan Fold Belt and Mongolia's Southern Gobi, two of the globe's leading porphyry belts, and the historical Condobolin mining field within the Cobar basin in NSW.The Company has already unlocked over $100 million of potential partner funding for multiple earlier stage and/or non-core porphyry projects. These initial deals have supported over 18,000 metres of drilling and over A$9m of partner funded exploration since late 2024, with management fees and exploration ramping up.Partner discussions are ongoing for its remaining 100% owned flagship projects that are all situated within existing porphyry camps containing over 20-million-ounce gold equivalent resource inventory.By having a significant portfolio of partner funded large porphyry projects, and a very focused capital efficient programs at the Condobolin and other sole funded projects, the Company is seeking to position Kincora as a leading institutional grade explorer in the public Australian and Canadian markets, and the leading project generator on the ASX.The Company's website is: www.kincoracopper.comThis announcement has been authorised for release by the Board of Kincora Copper Limited (ARBN 645 457 763)For further information please contact:Sam Spring, President and Chief Executive OfficerLaurie Thomas, Strategic Advisorsam.spring@kincoracopper.com or +61431 329 345laurie.thomas@kincoracopper.com or +1306 341 3826 Media contactJulia Maguire, Managing Director, The Capital Networkjulia@thecapitalnetwork.com.au or +61 2 7257 7338Executive office Subsidiary office Australia400 - 837 West Hastings StreetC/- JM Corporate ServicesVancouver, BC V6C 3N6, CanadaLevel 6, 350 Collins StreetTel: 1.604.283.1722Melbourne, VIC, Australia 3000 References:1 ASX release of Clancy Exploration Limited (now RareX Limited), titled "New Gold-Silver-Copper Discovery at Meritilga Prospect - Condobolin Project" dated March 20th, 2012, which can be obtained via the ASX website (www.asx.com.au). The Clancy results were reported in accordance with the version of the JORC Code existing prior to JORC 2012. Mining Associates has completed a review of sampling techniques and procedures dated January 31st, 2021, as outlined in the Independent Technical Report included in the ASX listing prospectus, which is available at: https://www.kincoracopper.com/investors/asx-prospectus. While the Company has no reason to believe the assay results are not reliable, the Company has not independently verified these results. The Company intends to conduct its own exploration programme as described in this release.2 ASX release of Clancy Exploration Limited (now RareX Limited), titled "Condobolin Project Yields Visible Gold and Potential Alluvial Gold" dated January 20th, 2012, which can be obtained via the ASX website (www.asx.com.au). The Clancy results were reported in accordance with the version of the JORC Code existing prior to JORC 2012. Mining Associates has completed a review of sampling techniques and procedures dated January 31st, 2021, as outlined in the Independent Technical Report included in the ASX listing prospectus, which is available at: https://www.kincoracopper.com/investors/asx-prospectus. While the Company has no reason to believe the assay results are not reliable, the Company has not independently verified these results. The Company intends to conduct its own exploration programme as described in this release.3 ASX release of Clancy Exploration Limited (now RareX Limited), titled "Gold and Silver Hits Extend Meritilga Lode" dated Jube 17th, 2013, which can be obtained via the ASX website (www.asx.com.au). The Clancy results were reported in accordance with the version of the JORC Code existing prior to JORC 2012. Mining Associates has completed a review of sampling techniques and procedures dated January 31st, 2021, as outlined in the Independent Technical Report included in the ASX listing prospectus, which is available at: https://www.kincoracopper.com/investors/asx-prospectus. While the Company has no reason to believe the assay results are not reliable, the Company has not independently verified these results. The Company intends to conduct its own exploration programme as described in this release.Forward-Looking StatementsCertain information regarding Kincora contained herein may constitute forward-looking statements within the meaning of applicable securities laws. Such forward-looking statements or information include but are not limited to statements or information with respect to: the Condobolin project, the drilling program in the Condobolin project, future growth, results and targets of Company drilling and other exploration activities and programs, open prior discoveries and larger causative porphyry center targets. Forward-looking statements may include estimates, plans, expectations, opinions, forecasts, projections, guidance or other statements that are not statements of fact. Readers are cautioned not to place undue reliance on forward-looking information and statements.Forward-looking information involves numerous risks and uncertainties, and actual results might differ materially from results suggested in any forward-looking information. These risks and uncertainties include, among other items: market prices, exploitation and exploration results, continued availability of capital and financing and general economic, market, or business conditions. Although Kincora believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. Kincora cautions that actual performance will be affected by a number of factors, most of which are beyond its control, and that future events and results may vary substantially from what Kincora currently foresees. Factors that could cause actual results to differ materially from those in forward-looking statements include: market prices; exploitation and exploration results; continued availability of capital and financing and general economic; market or business conditions; and, investor sentiment. Accordingly, readers should not place undue reliance on forward-looking information and statements. Readers are cautioned that reliance on such information and statements may not be appropriate for other purposes.The forward-looking statements are expressly qualified in their entirety by this cautionary statement. The information contained herein is stated as of the current date and is subject to change after that date. Kincora does not assume the obligation to revise or update these forward-looking statements, except as may be required under applicable securities laws.Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) or the Australian Securities Exchange accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/294502 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

由美國馬球協會(U.S. Polo Assn.)與 ESPN 共同贊助的「美國公開馬球錦標賽(R)」決賽圓滿落幕,為本季創下多項紀錄的美國馬球賽季畫下句點

佛羅里達州西棕櫚灘, 2026年4月28日 - (亞太商訊 via SeaPRwire.com) - 作為美國馬球協會(USPA)的官方運動品牌,U.S. Polo Assn. 以一場扣人心弦的決賽為美國馬球賽季畫下句點。2026年美國公開馬球錦標賽®(U.S. Open Polo Championship®)決賽於4月26日在佛羅里達州棕櫚灘縣的USPA國家馬球中心隆重登場。這場在標誌性的 U.S. Polo Assn. 體育場舉行的賽事,作為美國馬球界最負盛名的錦標賽,不僅呈現了頂尖的國際競技水準,更透過 ESPN 進行全球轉播,並在破紀錄的觀眾面前,於「冠軍週日」帶來了一場場內外皆熱烈迴響的精彩體驗。1. 美國公開馬球錦標賽獎盃與Pilot隊(從左至右:贊助人柯蒂斯·皮洛特、麥肯齊·韋茲、卡米洛·“傑塔”·卡斯塔尼奧拉、洛倫佐·查萬)2. Pilot隊的卡米洛·“傑塔”·卡斯塔尼奧拉在美國公開馬球錦標賽決賽中打入制勝一球,最終Pilot隊以15比10的比分鎖定勝局3. 鮑勃·布萊恩(右),史上最偉大的雙打網球選手之一,與美國馬球協會國家馬球中心網球職業選手斯科特·威廉姆斯(左)一同在美國公開賽馬球錦標賽決賽中主持賽前儀式性的拋硬幣環節4. 納什維爾鄉村歌手艾比·科恩在美國馬球協會國家馬球中心舉行的美國公開馬球錦標賽決賽上,為創紀錄的觀眾群演唱了國歌5. BTA已整裝待發,將在備受矚目的美國公開馬球錦標賽決賽中迎戰Pilot隊 6. 美國馬球協會(U.S. Polo Assn.)的模特兒們現身NPC的USPA專賣店,為美國馬球公開賽決賽助陣圖片來源:Agustina Fonda「Gauntlet of Polo®」系列賽的三項賽事中,第三場暨最終場賽事匯聚了 11 支頂尖隊伍以及眾多該運動中最傑出的選手,其中包括 10 級別的明星球員阿道夫·坎比亞索(Adolfo Cambiaso)、波羅托·坎比亞索(Poroto Cambiaso)、希拉里奧·烏洛亞(Hilario Ulloa)、托馬斯·帕內洛(Tomas Panelo),以及傑塔·卡斯塔尼奧拉(Jeta Castagnola)和巴托·卡斯塔尼奧拉(Barto Castagnola)。其他傑出選手還包括傑西·布雷(7分)、洛倫佐·查萬(7分)、麥肯錫·韋茲(6分)、魯菲諾·梅爾洛斯(6分)、尼科·埃斯科巴(6分)以及蒂米·杜塔(4分)等。無論是嶄露頭角的新星還是經驗豐富的選手,連同他們的馬匹夥伴,共同造就了這場競爭激烈的賽季,並在最終決賽中為所有觀眾呈現了一場精彩絕倫的盛宴。為擴大賽事的全球影響力,美國公開馬球錦標賽決賽將再次於ESPN各平台播出,由傳奇解說員克里斯·福勒(Chris Fowler)連續第二年擔任主持,並與肯尼·萊斯(Kenny Rice)、馬球名人堂成員亞當·斯諾(Adam Snow)以及卡爾·烏德-馬丁內斯(Karl Ude-Martinez)共同解說。該轉播亦可透過Global Polo的YouTube頻道收看,將美國公開馬球錦標賽的精彩賽事帶給全球觀眾。請查閱當地節目表以獲知播出時間。美國公開馬球錦標賽® 決賽一覽:· 決賽對陣:Pilot隊(#1 柯蒂斯·派洛特 - 0,#2 麥肯齊·韋茲 - 6, 第3種子 洛倫佐·查萬 - 7,第4種子 卡米洛·「傑塔」·卡斯塔尼奧拉 - 10)對決 BTA(第1種子 KC·克魯格 - 1,第2種子 史蒂夫·克魯格 - 5,第3種子 托馬斯·帕內洛 - 10,第4種子 伊格納西奧·「納奇」·維亞納 - 7)· 日期:2026年4月26日· 地點:佛羅里達州威靈頓的美國馬球協會國家馬球中心,位於美國馬球協會體育場場地· 最終比分:15(Pilot)- 10(BTA)· 最有價值球員:洛倫佐·夏凡(Pilot)· 最佳賽駒獎:《Open Texas》,騎師:洛倫佐·夏凡· 最佳表演馬(阿根廷育種):Open Silaba,騎手:Lorenzo Chavanne· 由 YETI 呈獻的 U.S. Polo Assn. 運動精神獎:史蒂夫·克魯格(BTA)· 斯基特·約翰斯頓 — 年度贊助商:KC 克魯格(BTA)· 慈善受贈機構:馬球培訓基金會(Pilot)及馬球博物館暨名人堂(BTA)· 轉播平台:ESPN 各平台(由克里斯·福勒主持,肯尼·萊斯、亞當·斯諾及卡爾·烏德-馬丁內斯共同參與),以及 Global Polo YouTube 頻道· 比賽精華:Pilot隊自首節起便掌控比賽節奏,始終保持著穩固的多球領先優勢,並在第三節中段將分差拉開至五球。儘管落後,BTA隊在半場休息時重新整頓,於下半場發起猛烈反攻,將分差縮小至僅一球。然而,Pilot隊始終未曾鬆懈,以精準的應對遏止對手氣勢,並重新擴大領先優勢。在最後一節,Pilot再添兩球,以15比10鎖定勝局,繼USPA金盃®後,成功在美國公開馬球錦標賽®決賽中連奪兩冠。洛倫佐·查萬(Lorenzo Chavanne)與卡米洛·「傑塔」·卡斯塔尼奧拉(Camilo ‘Jeta’ Castagnola)以各入七球的優異表現,成為本場決賽的得分王,為美國公開馬球錦標賽®決賽獻上精彩的進攻演出。週日,BTA 隊創下歷史,首度晉級美國公開馬球錦標賽®決賽,場上更有一對夫妻檔並肩作戰。這場比賽對這項運動而言亦具有重大意義,BTA 的女選手在此首度亮相美國公開馬球錦標賽,成為自 2002 年吉莉安·約翰斯頓(Gillian Johnston)奪得美國公開馬球錦標賽冠軍以來,首位晉級決賽的女性選手,這也體現了這項運動獨特的賽制——男女選手在場上並肩作戰。Pilot 隊以強勁氣勢挺進決賽,力求繼 2026 年 USPA 金盃奪冠後,再次蟬聯大滿貫冠軍。作為美國馬球協會(USPA)的官方運動品牌,U.S. Polo Assn. 在這場聲譽卓著的賽事中處處可見其蹤影,從為各隊及全體國家馬球中心(NPC)工作人員提供印有品牌標誌性「雙騎士」標誌的服裝,到在場館各處打造沉浸式的球迷互動體驗。該運動品牌更透過向本賽季所有賽事中由決賽隊伍選定的多家馬球及馬術慈善機構捐款,重申了對馬球運動及其社群的承諾。「從美國馬球協會國家馬球中心創下紀錄的賽季,到馬球界最受矚目的冠軍決賽之一,美國公開馬球錦標賽®持續為美國乃至全球的馬球運動樹立更高標竿,」管理著市值數十億美元的 U.S. Polo Assn. 品牌的 USPA Global 總裁兼執行長 J. Michael Prince 表示。「透過 U.S. Polo Assn. 的持續支持以及 ESPN 等平台,我們得以將這場冠軍決賽的活力與傳統傳遞給全球觀眾,同時持續吸引新粉絲,並為未來世代發展這項運動與品牌。」除了賽事本身,美國公開馬球錦標賽的冠軍週日更營造出充滿活力且以娛樂為主導的氛圍,深受老粉絲與新觀眾的共鳴。網球傳奇人物、布萊恩兄弟的鮑伯·布萊恩負責主持儀式性的擲硬幣環節,而納什維爾新銳歌手艾比·科恩則獻唱國歌。賓客們全天都能享受科恩的現場音樂演出,從阿薩多區的賽前時刻,到傳統中場草皮踩踏環節的歡快旋律皆然。U.S. Polo Assn. 更透過位於NPC的USPA商店內精心策劃的零售與生活風格體驗,進一步提升現場體驗,包括展示全球知名馬術藝術家愛德華多·馬奎茲(Eduardo Marquez)作品的驚艷馬球藝術畫廊、互動且引人注目的Briny Brim客製化帽吧的回歸,以及在商店門廊旁——緊鄰品牌馬球照牆處——免費供應的冰鎮限量版U.S. Polo Assn.玫瑰酒,為比賽日留下完美回憶。球迷們亦參與了標誌性的「踩草皮」傳統活動,並獲贈紅、白、藍三色紀念帽,以慶祝美國建國250週年。創立於1904年的美國公開馬球錦標賽,至今仍是檢驗美國馬球卓越水準的終極試金石,更是國際馬球賽程中的基石。每逢賽季,這項賽事皆吸引頂尖選手與熱情球迷齊聚「世界冬季馬術之都」威靈頓。B-Roll: https://f.io/lT0GXdwC關於 U.S. Polo Assn. 及 USPA GlobalU.S. Polo Assn. 是美國馬球協會(USPA)的官方運動品牌,該協會成立於 1890 年,是美國規模最大的馬球俱樂部及馬球運動員組織。憑藉數十億美元的全球業務規模,以及透過超過 1,200 家 U.S. Polo Assn. 直營店和數千個其他銷售據點的全球分銷網絡,U.S. Polo Assn. 在全球 190 多個國家為男女及兒童提供服飾、配件和鞋類產品。該品牌贊助全球各大馬球賽事,包括每年於棕櫚灘的 NPC 舉辦的「美國公開馬球錦標賽®(U.S. Open Polo Championship®)」,此為美國首屈一指的馬球錦標賽。透過與美國 ESPN、歐洲 TNT 和 Eurosport、印度 Star Sports 以及中東 BeIn Sports 的歷史性合作協議,由 U.S. Polo Assn. 贊助的多項世界頂級馬球錦標賽現已透過電視轉播,讓全球數百萬體育迷首次得以親睹這項令人熱血沸騰的運動。根據《License Global》的評選,U.S. Polo Assn. 長期與 NFL、PGA 巡迴賽及一級方程式賽車並列為全球頂尖運動授權商之一。此外,這個以運動為靈感的品牌更因全球業務拓展及體育內容而屢獲國際獎項肯定。憑藉其作為全球品牌的卓越成就,U.S. Polo Assn. 曾獲《富比世》、《財星》、《現代零售》及《GQ》等媒體報導,並登上雅虎財經與彭博社等全球眾多知名媒體平台。欲了解更多資訊,請造訪 uspoloassnglobal.com 並追蹤 @uspoloassn。USPA Global 是美國馬球協會(USPA)的子公司,負責管理市值數十億美元的運動品牌「U.S. Polo Assn.」。USPA Global 同時管理其子公司 Global Polo,該公司是全球馬球運動內容的領導者。欲了解更多資訊,請造訪 globalpolo.com 或 YouTube 上的 Global Polo 頻道。如需更多資訊,請聯絡:Stacey Kovalsky - VP, Global PR and CommunicationsPhone +001.561.790.8036 - E-mail: skovalsky@uspagl.comShannon Stilson - VP, Sports Marketing and MediaPhone +001.561.227.6994 - E-mail: sstilson@uspagl.com來源: U.S. Polo Assn. Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

邁威生物登陸港交所 早盤高開2.39% 核心ADC管線步入收穫期

香港, 2026年4月28日 - (亞太商訊 via SeaPRwire.com) - 4月28日,邁威(上海)生物科技股份有限公司(02493.HK,簡稱“邁威生物”)成功在香港聯合交易所主機板掛牌上市,成為又一家“A+H”兩地上市的生物科技公司,亦是首家AtoH的18A公司。邁威生物本次全球發售4713.02萬股H股,香港公開發售部分超額認購481.71倍,市場反響熱烈。強勁的認購態勢不僅為發行提供了穩固支撐,也折射出市場對於邁威研發管線與商業化前景的集體看好。邁威生物是一傢俱備創新研發及端到端產業化能力的中國製藥公司。其核心產品9MW2821(靶向Nectin-4)在中國尿路上皮癌臨床開發進度僅次於Padcev,且為全球首款進入宮頸癌關鍵III期試驗的同靶點ADC。該產品已獲得FDA三項快速通道認定及一項孤兒藥資格認定,並獲國家藥監局兩項突破性療法認定。公司正同步推進該產品針對多項適應症的III期臨床試驗,計畫於2027年提交尿路上皮癌和宮頸癌的NDA申請。若進展順利,9MW2821有望成為中國首款覆蓋多個實體瘤適應症的Nectin-4 ADC,潛在市場空間巨大。邁威生物已有君邁康(R)、邁利舒(R)、邁衛健(R)及邁粒生(R)四款產品實現商業化。2025年公司總收入達6.59億元人民幣,同比增長230%。對外授權合同總金額超過20億美元,貢獻顯著。公司與Disc、Calico等國際藥企達成的授權合約已帶來可觀的首付款和里程碑付款,充分驗證了其技術成果的國際化變現能力。公司的生產端亦具備國際標準。江蘇泰州生產基地符合中國GMP標準及歐盟EMA GMP標準,上海金山生產基地亦符合歐盟EMA GMP標準,為後續產品放量提供保障。邁威生物憑藉其差異化的ADC管線及已兌現的商業化能力,加速推進核心產品的上市進程,在全球腫瘤及年齡相關疾病領域持續鞏固其競爭優勢。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

華營控股以AI與數智科技主動領航 推動建造業安全、品質、效率全面升級

香港, 2026年4月28日 - (亞太商訊 via SeaPRwire.com) - 華營建築集團控股有限公司(下稱「華營控股」)作為香港建築業數智化轉型的領軍者,華營建築集團控股有限公司以人工智能、物聯網、數字孿生等前沿技術,構建覆蓋工地安全、工程管理、智能裝備的全鏈條科技體系。隨着香港最大單體智算中心落成,華營控股以成熟技術矩陣與項目實績,持續鞏固品牌信譽,以科技實力推動行業高質量發展。AI 天秤系統:智能塔吊守護工地安全華營控股於白田邨公營房屋重建項目率先規模化應用 AI 天秤系統,該方案融合 AI 視覺、激光及衛星定位技術,可自動識別吊鉤 3 米範圍內人員,識別準確率達 98%,並可於 10 秒內穩定吊鉤擺動,有效提升吊運效率 30%,從源頭杜絕高空作業盲區風險。有關系統由香港智能建造研發中心與香港房屋委員會聯合研發,憑藉卓越安全表現,榮獲 2025 年度建造業議會創新獎 — 建造安全類別獎項,現已成為公營房屋項目智能安全標配方案,獲房屋署及業界廣泛採納與認可。4S智慧工地+AI生態:構建主動式安全閉環華營控股自主研發之4S智慧工地系統已獲4S Label認證及商標註冊,涵蓋中央管理平台、AI 攝像頭監控、塔吊警報、VR 安全培訓、人員定位等十大模塊,實現「預警 — 處置 — 追溯」全流程可視化閉環管理。系統可實時識別未佩戴安全裝備、違規越界作業等潛在風險,並接入香港天文台氣象數據,強化惡劣天氣應變能力。目前該系統已全面覆蓋華營控股全港在建項目,現正申請建造業創新及科技基金認可,並逐步向大灣區輸出智慧工地整體解決方案。BIM+AI數字孿生:打造全生命周期數位化交付標杆華營 BIM 團隊是華營控股數智化轉型核心力量,2025 年於深圳設立研發中心,香港團隊多名註冊人員均持有 CCBC、CCBM、HKIBIM 等多項專業資格與會員資歷,配備專業軟硬件設備,全面支持智慧工地建設。目前 BIM 板塊服務已廣泛應用於多個重點項目,服務範疇由傳統建模升級至全生命周期數位化交付,涵蓋設計碰撞檢測、4D 進度模擬、5D 成本管控及數字孿生運維。華營控股明確 2026 年於至少一個項目實現 BIM 5D 完整應用,並以 360 度實景、點雲掃描與 BIM 模型疊加,實現施工進度可視化比對。元朗錦上路、將軍澳影業路、白田邨等多個公營房屋項目已全面應用 BIM 技術。在 2025 年度房委會「優質公共房屋建造及保養維修大獎」中,華營控股憑藉元朗錦上路項目,榮獲建築資訊模擬技術應用卓越承建商大獎,獲公營房屋領域高度認可。數字基建里程碑:香港最大單體智算中心落成本月,由華營控股承建之香港單體最大環球智算中心正式啟用。項目位於沙田火炭,合約額超 42 億港元,為華營控股第 5 個高端數據中心項目,總工期僅 756 日。項目可支撐千億級參數大模型訓練與推理,為香港人工智能、金融科技、生物醫藥等產業提供核心算力支持,成為推動香港數字經濟與新質生產力發展的重要基建。項目建設期間大量應用 BIM 精裝、智能監測及數位化協同管理,確保高標準按期交付,印證華營控股在新型基建領域的頂尖實力。華營控股作為深度參與香港數字經濟底層建設的承建商,已累積多個數據中心項目經驗,持續以專業承建能力與數智化優勢,為香港國際創科中心建設提供堅實支撐。  響應國家戰略 以科技穩信任、鑄未來華營控股緊扣國家「十五五」規劃與香港國際創科中心建設方向,深度對接北部都會區、公營房屋、數字基建等重點領域,堅持「安全為本、科技引領、品質至上」的經營理念,以數智技術強化安全管理、提升工程品質、嚴守合規底線。未來,華營控股將持續深化產研協同,推動 AI 天秤、4S 智慧工地、BIM 5D 等技術標準化與規模化應用,以科技驅動高質量發展,為香港建造業樹立「安全、智能、高效、可信」的行業標杆,助力香港更好融入國家發展大局。關於華營建築集團控股有限公司華營建築集團控股有限公司在香港從事建築業近60年,屬本地領先的建築承建商之一。集團在香港主要承接公私營機構的樓宇建築工程及RMAA工程項目。作為總承建商,集團負責(i)項目的整體管理;(ii)制定工作計劃;(iii)聘用分包商並監督其工程;(iv)採購建築材料;(v)與客戶及其顧問團隊溝通和協調;及(vi)保障符合安全、環境及其他合約要求。集團對外承接多項具代表性之工程項目,當中包括白田邨第十三期公營房屋重建項目、啟德1E區1號公營房屋發展項目、運用組裝合成建築法(MiC)的洪水橋及荃灣聯仁街過渡性房屋項目、觀塘市中心第二及第三區住宅綜合發展項目、灣仔軒尼詩道1號(One Hennessy)、麗晶酒店翻新工程、多座數據中心、各大專院校,包括香港中文大學、香港科技大學和香港理工大學在內的教學及科研樓、宿舍等,所承建之項目屢獲殊榮。媒體聯繫Wendy Zhu電話:+852 3950 5756郵箱:media@czcgl.com.hk Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

旭陽集團與杭氧集團簽署戰略合作協議 共築氫能全產業鏈新生態

香港, 2026年4月28日 - (亞太商訊 via SeaPRwire.com) - 2026年4月24日,旭陽集團有限公司(簡稱「旭陽集團」)與杭氧集團股份有限公司(簡稱「杭氧集團」)在杭州正式簽署戰略合作協議。雙方將立足京津冀雄和長三角區域,面向全國,在氫能供應體系、高端裝備國產化、技術創新及產業投資等領域開展全方位、深層次合作,共同推動我國氫能產業高質量發展。旭陽集團在工業副產氫領域擁有超過30年深厚積累,是全球最大的獨立焦炭生產商及供應商;全球最大焦化粗苯加工商、第二大高溫煤焦油加工商和己內酰胺生產商(按產能計),亦是中國最大的焦爐煤氣制甲醇生產商和京津冀最大的高純氫供應商(按產量計),中國旭陽集團(1907.HK)2019年3月成功在香港聯交所主板上市,已形成覆蓋「制-儲-運-加-用+研」的完整氫能產業鏈。杭氧集團股份有限公司(002430.SZ)2010年在深圳證券交易所上市,是世界一流的空分設備和低溫石化裝備供應商,中國氣體的產業開拓者和引領者,亦是國內第一台空分設備製造者;其大型、特大型空分設備產量和銷量全球第一,總體技術達到國際領先水平,在氣體運營及氫能技術研發方面具備領先優勢。此次合作是雙方優勢資源的戰略級整合,將旭陽氫源基礎與應用場景,與杭氧的裝備技術及氣體產業能力深度融合,為氫能全產業鏈生態建設注入強勁動力。聚焦三大合作方向,釋放協同發展新動能本次合作將重點圍繞氫能銷售與供應體系的共建、高端裝備國產化應用,以及技術創新與產業化落地展開。雙方將通過業務對接與資源協同,構建「液氫生產基地+區域儲氫樞紐+加氫站網絡」三級供應體系,共同拓展工業、交通、電子、醫藥、航天等終端市場。同時,雙方將聯合推進氫能領域關鍵裝備與系統的國產化進程,並在旭陽定州氫能生產基地共建氫能裝備測試與技術創新中心,聚焦液氫及加氫站核心部件的驗證與攻關,攜手申報國家級科研項目及行業標準。為進一步深化合作,雙方還擬共同出資設立合資公司,主營氫氣/液氫銷售、氫能裝備製造及技術服務,加速科技成果的產業化落地。合作前景:從資源優勢邁向全鏈引領此次戰略合作,標誌着旭陽集團氫能產業正加速從「資源優勢」向「全鏈優勢」躍升。通過與杭氧集團的強強聯合,旭陽將有效補齊在高端裝備和氣體運營網絡方面的關鍵環節,顯著提升氫能產品的市場覆蓋能力與流通效率,並藉助國產化裝備的規模化應用,降低全鏈條成本,增強核心競爭力。對於杭氧集團而言,合作將助其從傳統空分及低溫裝備領域,深度切入工業副產氫這一豐富的氫能源頭,拓展液氫及高純氫的應用場景,搶占氫能裝備與氣體服務的市場先機。面向未來,雙方將以此次合作為起點,構建可複製、可推廣的氫能產業生態。未來合資公司的設立更將為雙方帶來長期穩定的業務增長極,推動旭陽集團從焦化龍頭向全球領先的清潔能源解決方案提供商加速轉型,同時也助力杭氧集團實現從裝備製造向「裝備+服務+運營」的產業鏈延伸。在國家「雙碳」目標的引領下,旭陽與杭氧的攜手,將為我國氫能產業的高端化、規模化和國際化發展樹立新的標杆。杭氧集團黨委副書記童俊表示:「旭陽集團在工業副產氫及氫能應用場景方面具有獨特優勢。杭氧將全力支持雙方深度合作,共同推動我國氫能產業邁向高端化、規模化、國際化。」旭陽集團高級副總裁張英偉表示:「杭氧集團在低溫裝備和氣體運營方面擁有世界級的技術實力。本次合作是旭陽氫能產業的關鍵躍升,我們將充分發揮互補優勢,加快打造氫能產業生態,助力國家『雙碳』目標實現。」關於戰略合作協議,雙方已建立高層溝通機制和聯合工作小組,確保合作高效落地。未來,旭陽集團將繼續秉持開放、協同、共贏的理念,攜手產業鏈優秀夥伴,為構建清潔低碳、安全高效的現代能源體系貢獻旭陽力量。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Empowered by Pipeline and Forged by Technology: Mabwell Successfully Lists on the Main Board of HKEX

HONG KONG, Apr 28, 2026 - (ACN Newswire via SeaPRwire.com) - Driven by the continuous innovation in global biopharmaceutical technology, the steady rollout of favorable policies, and escalating clinical demands, the biopharmaceutical industry is ushering in a golden cycle of development. As a representative enterprise in China's innovative pharmaceutical sector, Mabwell (Shanghai) Bioscience Co., Ltd. (“Mabwell” or the “Company”, stock code: 02493.HK) has seized industry development opportunities by leveraging its profound R&D foundation, integrated whole-industry-chain advantages, and forward-looking global layout. Today, it officially listed on the Main Board of the Hong Kong Stock Exchange (HKEX), joining the biopharmaceutical sector of the Hong Kong stock market and opening a brand-new chapter in its international development.Reportedly, founded in 2017, Mabwell is a leading domestic innovative pharmaceutical enterprise, possessing premier innovative drug R&D capabilities and end-to-end whole-industry-chain capabilities that span from drug discovery to commercial sales. Since its establishment, the Company has been deeply engaged in therapeutic areas for major diseases such as oncology, immunology, ophthalmology, and orthopedics, and is committed to providing safer and more efficient innovative treatment solutions for patients worldwide.Rich and Diversified Product Pipeline Builds Core Competitive BarriersA rich and promising product portfolio serves as the core pillar for Mabwell’s steady development, as well as its key advantage in seizing first-mover opportunities in the market. With a long-term, deep-rooted presence in the innovative drug sector, the Company has built a diversified product pipeline featuring multiple categories and tiers. As of now, Mabwell has 4 commercialized products and 10 drug candidates: 1 in NDA stage,, 1 in preclinical stages, covering multiple high-potential therapeutic areas and supporting long-term growth.Mabwell’s self-developed core product, 9MW2821, fully demonstrates the Company’s leading edge in the ADC field. 9MW2821 is the most advanced among all Nectin-4-targeting ADCs for urothelial carcinoma (“UC”) in China in terms of clinical development progress, and only second to the globally blockbuster drug Padcev. Meanwhile, it is also the first Nectin-4-targeting ADC globally to enter the pivotal Phase III clinical trials for cervical cancer (“CC”), and triple-negative breast cancer (“TNBC”), boasting extensive market potential.Beyond 9MW2821, Mabwell continues to advance the R&D of ADC candidates targeting other novel targets and has built a comprehensive ADC pipeline portfolio. Its pipeline includes 7MW3711, an ADC specifically targeting B7-H3 (an immune checkpoint protein), and 7MW4911, an ADC specifically targeting CDH17. This layout further diversifies the Company’s footprint in oncology treatment and steadily consolidates its leading advantages in the ADC track.Notably, Mabwell has also strategically prioritized the layout of product pipelines covering monoclonal antibodies (“mAbs”), TCE bispecific antibodies, fusion proteins and small molecule drugs, fostering a pattern of coordinated development across multiple product categories. Its R&D portfolio includes: 9MW3811, a humanized monoclonal antibody targeting IL-11 for the treatment of fibrosis -related diseases and cancers; 9MW1911, the first domestically developed drug candidate approved for clinical development in China targeting ST2; 9MW3011, a recombinant humanized TMPRSS6 targeting mAb among the leading TMPRSS6-targeting therapies in terms of development status globally; and 6MW5311, the world’s first LILRB4/CD3-targeted TCE bispecific antibody filed for clinical trials. These candidates keep expanding the boundaries of the Company’s innovative drug research and development.Outstanding commercialization capabilities, expanding a global market footprintLeveraging its fully integrated industry chain capabilities and forward-looking commercialization strategy, Mabwell (Shanghai) Bioscience Co., Ltd. has continued to deliver tangible commercialization outcomes. In 2025, the Company’s Junmaikang® obtained marketing approval in Indonesia, while Mailisheng® and Maiweijian were approved for commercialization in Pakistan, marking steady progress in its international commercialization efforts.Since 2022, the Company has actively expanded overseas collaborations, entering into multiple landmark international partnership agreements and securing corresponding revenue-sharing arrangements. It has successfully penetrated emerging markets including Brazil, Indonesia, Saudi Arabia, and countries along the Belt and Road Initiative, establishing an extensive global commercial network.In terms of global partnerships, Mabwell has further deepened its international presence. In January 2023, the Company entered into an exclusive licensing agreement with Disc Medicine for 9MW3011, under which it is entitled to receive up to US$412.5 million in upfront payments, milestone payments, and royalties. In June 2025, it reached an exclusive licensing agreement with Calico Life Sciences for 9MW3811, with total potential consideration exceeding US$600 million, including upfront, milestone, and royalty payments. In October 2025, the Company signed an exclusive licensing agreement with Kalexo Bio for a novel dual-target siRNA candidate drug, further expanding the breadth and depth of its international market collaborations.Powerful Technology Platforms Lay a Solid Foundation for Innovation-Driven GrowthPowerful technology platforms serve as the core engine for sustained innovation at Mabwell, and are also pivotal to building differentiated competitive advantages. With deep commitment to technological R&D, the Company has established four core ADC technologies for which we possess proprietary intellectual property rights, providing strong support for the development of innovative drugs.Among these, DARfinity is a self-developed site-specific conjugation process that enables precise drug molecule conjugation; IDconnect is an optimized design of linker molecules that enhances the stability of the linkage between the antibody and toxins; Mtoxin is a class of camptothecin-based novel toxic molecules that are used as the “warhead” in the ADC to kill the targeted cells, providing more potent target cell killing effects; LysOnly is an innovative structure that allows conditional release of toxins, effectively improving the overall safety and efficacy of ADC drugs.These four proprietary technologies serve as the core pillars of our site-specific conjugation ADC development platform, synergistically enabling the Company to develop ADC products with better uniformity, stability, purity, and a superior efficacy and safety profile. This significantly improves pipeline R&D efficiency, allows rapid response to clinical and market demands, and continuously consolidates the Company's leading position in the ADC field.In addition, Mabwell continues to develop and upgrade other core technology platforms, forming a multi-technology synergistic development system. These platforms include the integrated high-efficiency antibody discovery platform and the T-cell engager (TCE)-based bi/tri-specific antibody development platform, among others. The TCE-based bi/tri-specific antibodies developed on these platforms can simultaneously and specifically bind to tumor-associated antigens and the T-cell CD3 epitope, thereby laying a solid technical foundation for the Company's strategic positioning in the field of immunotherapy.From an industry perspective, the global biopharmaceutical sector, as a core segment, has continued to gain momentum in recent years. The global oncology drug market grew from US$143.5 billion in 2019 to US$253.3 billion in 2024 with a CAGR of 12.0%, and is expected to further increase to US$375.9 billion, and US$548.2 billion in 2028, and 2032 respectively, with CAGRs of 10.4% from 2024 to 2028 and 9.9% from 2028 to 2032, respectively. This trend presents substantial growth opportunities for leading industry players like Mabwell, which possess core technologies and a globalized footprint.Driven by in-house R&D, supported by integrated end-to-end capabilities across the entire industry chain, and guided by a long-term global strategy, Mabwell continues to advance steadily in the innovative pharmaceutical sector. Leveraging a robust product pipeline, strong technological expertise, and well-established commercialization capabilities, the Company has built a solid competitive position. Its successful listing in Hong Kong will further accelerate the development of its core products, enhance its commercialization strategy, and strengthen its core competitiveness. This, in turn, is expected to position the Company at the forefront of the biopharmaceutical wave, with strong long-term growth potential that merits close market attention. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

51WORLD Grants 940,200 RSUs for the First Time via Share Repurchase

HONG KONG, Apr 28, 2026 - (ACN Newswire via SeaPRwire.com) - Beijing 51WORLD Digital Twin Technology Co., Ltd. (“the Company”, Stock Code: 6651.HK) announced on 27 April 2026 the first grant of 940,200 restricted share units (RSUs) to 303 employees under its 10-year RSU Scheme, representing approximately 0.23% of the Company’s total issued shares.The underlying shares will be sourced from existing H Shares acquired by the Trust on the secondary market and/or treasury H Shares repurchased by the Company using its own funds. Vesting of the award shares shall be 25% after 12 months from acceptance, and the remaining 75% shall vest in 12 quarterly instalments at 6.25% each until fully vested.The RSU Scheme is intended to align the interests of the core team with the long-term development of the Company and enhance the incentive mechanism for talent attraction and retention. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Buffalo Potash Announces Preliminary Economic Assessment for Disley Project with After-Tax NPV of US$1.1B and IRR of 30%; Releases Results from Maiden 43-101 Mineral Resource Estimate

Saskatoon, Saskatchewan--(ACN Newswire via SeaPRwire.com - April 27, 2026) - Buffalo Potash Corporation (TSXV: BUFF) (OTCQB: BLPTF) (the "Company" or "Buffalo") is pleased to announce the completion of a Preliminary Economic Assessment ("PEA") and concurrent release of its maiden 43-101 Mineral Resource Estimate for its 100%-owned Disley Potash Project (the "Disley Project"), located in Saskatchewan, Canada.The PEA has been filed and can be found under the Company's profile on SEDAR+ (www.sedarplus.ca) and on the Company's website (www.buffalopotash.ca).PEA & Mineral Resource Estimate Highlights Total production of 1,000,000 tonnes per annum (TPA) of K62 granular-grade Muriate of Potash (MOP) and 125,000 TPA of K62 soluble grade MOPAfter-tax NPV(1)(8) of US$1.1B and IRR(1) of 30%US$639M initial CAPEX estimate, including US$128M in contingencyEstimated US$55/t MOP OPEX (Table 4)Measured and indicated tonnage of 1,671.5 million metric tonnes at an average grade of 34.8% KCl, yielding 582 million tonnes of KClOver 50 years of mine life at 1,125,000 TPA based on current resource estimate (Table 2)(2)The advancement of a Feasibility Study ("FS") for Disley East and Disley West (the "HLD Mines") will run concurrent with Initial Production Module ("IPM") construction, with FS completion representing the key decision gate for proceeding to construction of Disley East and Disley West(3)(2) Based on Measured and Indicated resource estimate of 582Mt at 34.8% KCl.(3) The PEA does not constitute a feasibility study and does not demonstrate economic viabilityMr. Steve Halabura P.Geo., Buffalo Chief Executive Officer, commented: "Since founding Buffalo Potash in 2018, the team and I have invested years of disciplined work — geological, technical, and strategic — to systematically unlock the potential of modular selective solution potash mining in Saskatchewan, the key being Buffalo's Disley Project. Having spent my career working in Saskatchewan potash, I had a strong conviction from the beginning that Disley had a substantial resource endowment, and this Mineral Resource Estimate confirms exactly that. The PEA illustrates both low capex per tonne and operating cost per tonne, as well as setting a new environmental standard for how potash production should look in the 21st century — no tailings stored on surface and minimal freshwater usage." Mr. Halabura continued: "The team and I believe the Disley Project represents the next generation of Saskatchewan potash solution mining and are excited to begin development of the Initial Production Module, which will be the first leg of this buildout and is expected to bring soluble-grade potash production online within the next 12 months. During the development of the Initial Production Module, we will also test our patent-pending Vortex Crystallizer, alongside an industry standard crystallizer, which has the potential to significantly reduce the capex of the Initial Production Module and further potential build-outs. With global attention turning to the security of critical supply chains, the urgency to bring reliable, jurisdiction-stable potash production online has never been greater. This is a proud moment for our team, our shareholders, and the stakeholders that have supported us along the way — and we are just getting started."Table 1: PEA SummaryLine ItemUnitsTotal Project Production Rate MOPTPA1,000,000Production Rate Soluble GradeTPA125,000Total Initial CAPEXUS$ million639CAPEX per Tonne CapacityUS$/tonne568Average Unit OPEXUS$/tonne55MOP Price (25-year avg.)US$/tonne393.6(4)Soluble Grade Price (25-year avg.)US$/tonne373.6(5)Pre-Tax NPV(1) (8%)US$ million1,534.67Pre-Tax IRR(1)%35Post-Tax NPV(1) (8%)US$ million1,085.47Post-Tax IRR(1)%30Steady-State Annual RevenueUS$ million442.5Steady-State Annual EBITDAUS$ million251.0 (4) LoM average price of Granular MOP, produced by Disley East and Disley West(5) LoM average price of Soluble Grade MOP, produced by IPMThe PEA is preliminary in nature and includes inferred mineral resources, which are considered too speculative geologically to have the economic considerations applied to them that would enable them to be categorized as mineral reserves. There is no certainty that the PEA will be realized.PEA & Mineral Resource Estimate OverviewThe PEA was prepared by Micon International Co Limited ("Micon") in accordance with National Instrument 43-101 Standards of Disclosure for Mineral Projects and evaluates the development of the Disley Project as a phased potash solution mining operation. The PEA has an effective date of April 15, 2026 and is based on a Mineral Resource Estimate ("MRE") developed concurrently by Micon with an effective date of April 15, 2026, incorporating historical assay data from legacy drilling programs as well as results from Buffalo Potash's 2026 confirmation drill program. The PEA contemplates a phased development approach across three production facilities on the Disley property:The Initial Production Module ("IPM") - is a low-capital entry point designed to bring 125,000 tonnes per year of soluble grade MOP to market;Disley East - a full-scale HLD Mine on the east segment of the Disley Project, with a production capacity of 500,000 tonnes per year of granular MOP; andDisley West - a full-scale HLD Mine on the west segment of the Disley Project, with a production capacity of 500,000 tonnes per year of granular MOP.Successful construction of the IPM is anticipated to provide technical data used in the completion of the concurrent FS and would, subject to the results from the FS and a positive construction decision, be followed by the potential concurrent development of the Disley East and Disley West HLD solution mines. If fully developed, the Disley Project is designed to have the capacity to produce 1,000,000 TPA of granular MOP and 125,000 TPA of soluble grade MOP ("Full Production Capacity").The MRE indicates a resource base that substantially exceeds the project's current design requirements, which, if successfully developed, would position the Disley Project as a long-life asset. This is consistent with the generational mine lifecycles typically associated with Saskatchewan potash operations, though there is no certainty that resources will be converted to reserves or that any particular mine life will be achieved.Table 2: Mineral Resource EstimateCategoryTonnage (Mt) Avg KCl GradeAvg K2O GradeKCl (Mt)K2O (Mt)Measured399.734.82%22.00%139.287.9Indicated1,267.434.84%22.01%441.5278.9Inferred2,663.234.96%22.08%930.9588.1 Table 2 Notes:The effective date of this MRE is April 15, 2026.Dr. Ryan Langdon, Ph.D, CGeol, of Micon is the QP responsible for this MRE.The MRE has been classified in the Measured, Indicated and Inferred categories.An average specific gravity (SG) value of 2.08 g/cm3 was used.Conversion between KCl and K2O was made using the formula KCl = K2O * 1.583The MRE used economic assumptions for HLD mining. A deduction was made to account for the presence of mining anomalies not detected by existing drill holes and seismic lines. The values used are 5% for Measured, 9% for Indicated and 25% for Inferred.The block model supporting the resource is orthogonal and has a block size of 50 m x 50 m x 0.9 m.The mineral resources described above have been prepared in accordance with the current Canadian Institute of Mining, Metallurgy and Petroleum Standards and Practices.Numbers have been rounded to the nearest million tonnes. Differences may occur in totals due to rounding.Mineral Resources are not Mineral Reserves as they do not have demonstrated economic viability. The quantity and grade of reported Inferred Mineral Resources are uncertain in nature and there has been insufficient exploration; however, it is reasonably expected that a significant portion of Inferred Mineral Resources could be upgraded into Indicated Mineral Resources with further exploration.Micon's QP has not identified any legal, political, environmental, or other factors that could materially affect the potential development of the mineral resource estimate.Figure 1: Core Samples from the 7-10 Hole on the Disley ProjectTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/12107/294332_592822e3642ebbb0_001full.jpgMining MethodBuffalo intends to develop the Project using solution mining, a well-established approach that has been successfully deployed across Saskatchewan for more than 50 years. Solution mining is widely recognized as a reliable and efficient technique for extracting potash from laterally continuous deposits, notably used at both neighboring properties of the Disley Project — the K+S Bethune mine and the Mosaic Belle Plaine mine.Building on this proven foundation, Buffalo holds a patent on an enhanced solution mining approach known as Horizontal-Line-Drive Selective Solution Mining ("HLD Mining"), which is the installation of commercially proven oil and gas injection systems within horizontal wells. This method is designed to optimize efficiency, reduce overall capital intensity, and significantly limit freshwater requirements, while remaining grounded in the principles of traditional solution mining.Following underground dissolution, potash-rich brine is recovered to surface and processed through crystallization, drying, and compaction to produce a finished potash product ready for local delivery or export via existing road and rail infrastructure that currently runs adjacent to the Disley Property.Initial Capital Expenditure (CAPEX) The initial capital cost estimate has been prepared in line with the Class 4 definition outlined by AACE International standards, with a contingency of 25% applied to the IPM, Disley East, and Disley West components.Mechanical equipment represents the largest component of initial capital expenditure at approximately 38% of Total Project initial CAPEX. For Disley East and Disley West, the mechanical scope encompasses the full processing train required to produce export-grade granular MOP, including crystallization, debrining and drying, compaction and glazing, soluble product screening, and product storage and loading. For the IPM, the mechanical scope includes a crystallizer, pumps, tanks, pipework, centrifuge, dryer, and baghouse. Total initial capital expenditure across all three facilities is US$639 million, as summarized in the table below.Table 3: Initial CAPEX SummaryDescription IPMDisley EastDisley WestTotal Project(US$ million)(US$ million)(US$ million)(US$ million)Site Works0.711.311.323.3Concrete-5.65.611.2Structural Steel1.29.39.319.9Mechanical15.1113.3113.3241.7Piping0.214.914.930.0Electrical-15.015.029.9Instrumentation0.12.92.95.9Architecture0.019.619.639.2Minor Mechanical4.72.42.49.4General Construction1.413.313.328.0Indirects-36.136.172.3Contingency5.860.960.9127.7Total Capital Expenditure(6)29.2304.7304.7638.6  (6) For modelling purposes, the total capital expenditure estimate for the PEA assumes use of an industry standard crystallizer instead of Buffalo's patent-pending Vortex Crystallizer.Sustaining capital of US$483 million (US$17/t MOP) over the life of mine comprises an annual provision of 2% of original fixed plant and surface infrastructure costs, plus US$10/t MOP for the drilling, completion and tie-in of replacement wells — the dominant component of sustaining capital — based on each set of three wells yielding 500,000 tonnes over an approximate 5-year useful life.Operating Expenses (OPEX)Buffalo Potash's estimated operating cost of US$55/t MOP reflects the structural advantages of operating in Saskatchewan, a mature potash jurisdiction with competitive industrial energy rates, an established skilled workforce, and existing road and rail infrastructure adjacent to the Disley Property enabling low-cost delivery to both domestic and export markets. Buffalo management anticipates these fundamentals position the Disley Project to be among the lowest-cost potash producers upon reaching full production.Table 4: OPEX SummaryItemDescription1,125,000 TPA(US$ million)IPM Contingency$14.49/t applied to IPM production only1.8Wellfield Power500 Hp at $0.063/kWh1.8Processing Power19,356 Hp at $0.063/kWh18.0Drilling$25,000/day; 45 days/yr0.1Pipes, Pumps, ValvesSteaming & general maintenance0.8InstrumentationMonitoring & controls0.4Labour32 staff7.8Natural Gas$386/1000m³ incl. carbon tax19.6Maintenance5% of major equipment capital5.4ReagentsDedust oil & anticake amines2.0Water$2.20/m³; 45 m³/hr1.3General & Admin SupervisionManagement & safety1.9Admin SuppliesOffice & admin supplies0.8Total Annual OPEX61.7OPEX US$/t MOP55 / tonne Economic AssumptionsThe economic analysis evaluates the Disley Project as a phased development consisting of the IPM to establish early cash flow, followed by the full-scale HLD Mine comprising Disley West and Disley East. The IPM was evaluated as a standalone project, with the HLD Mine (Disley East and Disley West) assessed on an incremental basis and in combination with the IPM as an overall project. A Discounted Cash Flow ("DCF") model was constructed with the following assumptions:All costs and revenues are expressed in constant, first quarter 2026 money terms, with no provision for escalation or inflation;Capital and operating cost estimates denominated in Canadian dollars have been converted to US dollars at an exchange rate of CAD 1.38 per USD;A discount rate of 8% has been applied on an all-equity basis;The pre-tax results presented include the Saskatchewan Potash Production Tax (PPT) and royalties but exclude federal and provincial corporate income tax. The after-tax results include corporate income tax (Saskatchewan 12%, Federal 15%);The IPM ramps up over 3 months at 50% of nominal capacity; Disley West and Disley East have a 6-month ramp-up period at 50% of capacity, with the Disley East being deferred by a 3-month offset from the West Section;It is assumed the IPM is scheduled to begin construction July 2026 with commercial operations starting January 2027;It is assumed that a positive construction decision will be reached on Disley West and Disley East. Disley West is scheduled to begin construction July 2027, with operations beginning July 2029. Construction at Disley East is scheduled to be the final facility developed, with construction beginning October 2027 and operations beginning October 2029;Soluble grade MOP produced by the IPM is sold locally, incurring a transport cost of US$10/t compared to US$43/t for export grade granular MOP railed FOB Vancouver; soluble grade MOP is priced at a US$20/t discount to granular, reflecting a life-of-mine average of US$373.6/t versus US$393.6/t FOB Vancouver;In addition to MOP, the IPM will produce 50,000 m³ per year of KCl brine that may be attractive to regional oilfield services customers at an average transport cost of US$10/m³;Payback period is measured from the start of construction to the point at which cumulative cash flow turns positive; andAlthough the project's mine life is anticipated to extend beyond a 25-year time frame, the NPV(1) and IRR(1) calculations reflect a 25-year "LoM" period.The primary input parameters for the DCF model are outlined in the table below.Table 5: Summary of Inputs for Economic AnalysisInput ParametersUnitValueEvaluation Base Date - IPMDate2026-07-01Evaluation Base Date - Disley East & Disley WestDate2027-07-01Sales: HLD Mine MOP Sales (granular)TPA1,000,000Sales: IPM MOP (soluble)TPA125,000Sales: KCl Brinem3/yr50,000Price: Granular MOP (FOB Vancouver) 25-year averageUS$/t394Price: Soluble MOP 25-year averageUS$/t374Price: KCl BrineUS$/m343Transport Costs: Granular MOPUS$/t43Transport Costs: Soluble MOPUS$/t10Transport Costs: KCl BrineUS$/m310Corporate Tax (Sask. + Canada)%27%Contingency for CAPEX%25%Discount Rate%8%NPV calculationYears25 The Disley East and Disley West mines have a start date of construction later than that of the Initial Production Module, and their IRR(1), NPV(1) and Payback periods are all calculated from that later date, while the overall Project results reflect the start date of the IPM. The individual IPM phase has a payback period of 1.1 years, while Disley East and Disley West each respectively have payback periods of 2.9 years. The total Project payback of 4.7 years reflects an earlier calculated start date at the time of first production at the IPM, prior to first production from Disley East and Disley West.Table 6: Summary of OutputsMetricUnitTotal ProjectInitial CAPEXUS$ million639OPEXUS$55 / tonnePre-Tax NPV(1) (8)US$ million1,534Pre-Tax IRR(1)%35%Post-Tax NPV(1) (8)US$ million1,085Post-Tax IRR(1)%30% The Disley ProjectThe Disley Project is located approximately 50km northwest of Regina and covers 10,610 hectares (Crown and Freehold mineral rights). The property is situated immediately adjacent to the east of the K+S Bethune potash solution mine and north of the Mosaic Belle Plaine potash solution mine — both of which are amongst the largest producing potash solution mines in the world. In the opinion of management, the Disley Project is in one of the most favorable areas of Saskatchewan for potash solution mining (see Figure 2) as evidenced by the success of these neighboring projects(6).Figure 2: The Disley Property Situated Amongst Major Potash Solution Mines(7)To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/12107/294332_592822e3642ebbb0_002full.jpgAbout Buffalo PotashBuffalo Potash is an emerging Saskatchewan-based potash developer pursuing a modular approach to selective solution mining through its patented Horizontal Line-Drive (HLD) technology. Buffalo is advancing the Disley Project — located next to several of the most prominent currently producing potash solution mines in the world — with the objective of establishing capital-efficient, lower-impact potash production in one of the world's leading potash jurisdictions.Qualified PersonThe scientific and technical information contained in this news release has been reviewed and approved by Douglas F. Hambley, PhD, PE, P.Eng., PG, an independent consultant of the Company and Qualified Person as defined under NI 43-101 Guidelines. Dr. Hambley is a globally recognized expert in potash geology and mine development and has assisted Micon in their preparation of the MRE and PEA.All related and pertinent information has also been reviewed for this news release by Jared Galenzoski, P.Geo, FIMMM as an independent consultant and Qualified Person as defined under NI 43-101. Mr. Galenzoski is also an expert in several potash-related fields and has assisted Micon in their preparation of the MRE and PEA.Technical Report and Qualified PersonsFor more information in respect of the Disley Project, including with respect to key assumptions, parameters, and methods used to estimate the MRE, data validation and QA/QC procedures, and the basis, qualifications and assumptions for the PEA, please refer to the entirety of the Technical Report prepared by Ryan Langdon, PhD, P.Geol.; Jack Nagy, PEng; Christopher Jacobs, CEng., MIMMM; and Richard Thompson, CEng, MiChemE. Each of the aforementioned persons is considered a "Qualified Person" for the purposes of NI 43-101 and has reviewed and approved the scientific and technical disclosure contained in this news release. No limitations were imposed on their verification process. Readers are cautioned to review the entirety of the PEA as it contains additional disclosures material to the matters discussed in this press release.Notes(7) The K+S Bethune potash solution mine and north of the Mosaic Belle Plaine potash solution mine (together, the "Adjacent Properties") may each be considered an "adjacent property" (within the meaning of NI 43-101) to the Company's Disley Project. The Company does not have any interest in either of the Adjacent Properties. The Company believes this context is useful in illustrating the proven endowment of the district, while noting that mineralization on adjacent or nearby properties is not indicative of mineralization on the Company's Disley Project. There is no guarantee that the Disley Project will yield comparable results to any of these mines.ContactSteve Halabura, P.Geo. | Chief Executive Officer & DirectorEmail: steve@buffalopotash.ca | Phone: 1-306-220-7715(1) Non-GAAP Financial MeasuresNet Present Value ("NPV") and internal rate of return ("IRR") are forward-looking financial measures used by management to evaluate the economic potential of the Disley Project, as estimated in the PEA. These measures do not have standardized definitions under IFRS and may not be comparable to similar measures disclosed by other issuers.NPV represents the sum of discounted future after-tax cash flows projected over the 25-year evaluation period at a discount rate of 8%, net of initial and sustaining capital expenditures. The most comparable IFRS measure is net income (loss); however, NPV is a forward-looking measure that reflects projected future cash flows and cannot be directly reconciled to historical net income. IRR represents the discount rate at which NPV equals zero across the project's projected cash flows.These measures should not be construed as alternatives to net income, comprehensive income, or cash flows from operations as determined in accordance with IFRS. Readers are cautioned that these measures reflect PEA-level estimates and are subject to the risks and uncertainties disclosed under "Forward-Looking Information" below.Forward-Looking InformationThis news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable Canadian securities legislation and the United States Private Securities Litigation Reform Act of 1995. Forward-looking information is generally identifiable by the use of words such as "believes," "may," "plans," "will," "anticipates," "intends," "could," "estimates," "expects," "forecasts," "projects," "targets," "schedules," or similar expressions, and the negative of such expressions.Forward-looking information in this news release includes, but is not limited to, statements regarding: the results, assumptions, and projections contained in or derived from the PEA and Mineral Resource Estimate for the Disley Project, including projected production rates, capital and operating costs, NPV, IRR, payback periods, and mine life; the anticipated timing and phasing of construction and commercial production for the IPM, Disley East, and Disley West; the Company's ability to secure permitting, financing, and all necessary regulatory approvals; the anticipated cost and technical performance of the HLD Mining method; expectations regarding MOP and soluble grade potash pricing, transportation costs, and market access; and the Company's broader development plans and strategy for the Disley Project.Forward-looking information is based on management's reasonable assumptions, estimates, analysis, and opinions made in light of its experience and perception of historical trends, current conditions, and expected future developments, as well as other factors that management believes are relevant and reasonable in the circumstances as of the date such statements are made. Key assumptions underlying the forward-looking information include, but are not limited to: the accuracy of the Mineral Resource Estimate and PEA, including geological, engineering, and cost assumptions; no material adverse changes to commodity prices, exchange rates, or tax and royalty regimes; the availability of financing on acceptable terms; the Company's ability to obtain necessary permits and approvals on anticipated timelines; and the continued availability of equipment, personnel, and infrastructure.Forward-looking information is subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied, including: the inherent uncertainty of PEA-level studies and the possibility that actual capital costs, operating costs, and production rates differ materially from estimates; changes in potash or fertilizer market prices; fluctuations in currency exchange rates, particularly the Canadian dollar relative to the US dollar; the risk that permitting, financing, or regulatory approvals are not obtained on anticipated timelines or at all; risks related to the development, commissioning, and operation of novel mining technology; risks inherent to solution mining operations; and general business, economic, competitive, political, and social risks and uncertainties.A PEA is preliminary in nature and includes Inferred Mineral Resources that are considered too speculative geologically to have the economic considerations applied to them that would enable them to be categorized as Mineral Reserves. There is no certainty that the PEA will be realized. Mineral Resources that are not Mineral Reserves do not have demonstrated economic viability.Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated, or intended. The forward-looking information contained herein is made as of the date of this news release, and the Company disclaims any obligation to update or revise such information except as required by applicable securities laws.Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/294332 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Standard Chartered GBA Business Confidence Indices highlight resilience of GBA corporates despite Middle East uncertainties

HONG KONG, Apr 27, 2026 - (ACN Newswire via SeaPRwire.com) - Standard Chartered and the Hong Kong Trade Development Council (HKTDC) jointly released the latest Standard Chartered Greater Bay Area Business Confidence Index (GBAI), revealing that business sentiment among companies in the Greater Bay Area (GBA) remained stable in the first quarter of 2026 despite ongoing geopolitical and trade headwinds, notably oil price shocks and continued repercussions from the Middle East conflict.Maintaining Momentum Amid HeadwindsThe Q1 findings largely captured activity and business sentiment since the Middle East conflict began in late February, which has remained highly uncertain and weighed on overall business and market sentiment.Despite a reduced appetite for expansion amid persistent geopolitical uncertainties, business sentiment remained steady across the GBA. The “current performance” index for business activity in Q1 edged down marginally to 49.9 from 50.3 in the previous quarter, while the “expectation” index moderated to 50.4 from 51. Both indices hovered around the 50-neutral mark, indicating GBA corporates’ resilience, supported by favourable policies announced by the Chinese Government aimed at boosting the domestic economy, which in turn would partially offset the fallout of the Middle East conflict.The “current performance” index came down mainly driven by “raw material inventory”, “fixed asset investment” and “financing scale”. The latter two readings were believed to reflect more cautious sentiment among businesses in light of the Middle East conflict. Meanwhile, “production/ sales”, “prices of finished goods/ services” and “profits” all experienced quarter-on-quarter expansion.The “expectations” index remained modestly positive, despite heightened external uncertainties. “New orders” held steady at 51.5, while “prices of finished good/ services” rose to 58.5. However, “profits” fell below the 50-watershed level, implying surveyed companies did not view price increases as sufficient to offset a likely rise in energy and material costs.Hong Kong to Sustain a Still-solid Growth PaceBy city, Hong Kong is expected to maintain a solid performance going forward. Although both the “current” and “expectation” sub-indices edged down to 52.7, these readings still comfortably stayed in expansionary territory, supported by improvements in “financial services” and “innovation and technology” sectors.Tommy Wu, Senior Economist, Greater China and North Asia, Standard Chartered, said: “In addition to the initial impact of surging global energy and freight costs, there are concerns about second-round impacts, such as higher input costs and weaker global demand. This is aligned with the latest reading, which shows a 2.3-point decline in “new export orders” to 47.5 for “current performance”, indicating a more cautious outlook for export demand. With the prolonged Middle East conflict, we anticipate global energy prices to be higher for longer and the second-round effects to become more visible in the coming months. These will likely weigh on business sentiment and appetite on making fixed investment. Nevertheless, Hong Kong has once again demonstrated its resilience amid market turbulence, and such resilience is expected to attract more global capital into HKD and Renminbi assets as safe-haven allocation.”Demand-boosting Measures Favour GBA BusinessesThe survey also investigated the impacts of a series of supportive policies from the Chinese government aimed at stimulating domestic demand in its thematic section. Among the new policy measures introduced by the Ministry of Finance in January, most respondents cited “loan interest subsidies for small, medium and micro-sized enterprises” (38.4%), “large-scale equipment upgrade subsidies” (36.9%) and “consumer goods trade-in subsidies” (31.7%) as the top domestic demand-boosting policies likely to have the most positive impact on their business.Wing Chu, Deputy Director of Research, HKTDC, said: “Demand-boosting stimulus is generating tangible benefits for GBA companies, helping to cushion external challenges amid the Middle East conflict. Targeted support, including loan interest subsidies, alongside measures aimed at stimulating consumer spending, is underpinning demand and supporting business activity across the GBA. Overall, policy-led demand support continues to serve as a meaningful tailwind for GBA businesses. While cost pressures and market competition remain key concerns, respondents are considering stepping up investment in talent and market promotion to sustain further business growth.”While many respondents believe stimulative policies could benefit their businesses by boosting online sales (36.6%) and reducing operating costs (33.8%), challenges faced by GBA corporates remain. Specifically, 54.9% of respondents identified labour costs as the biggest pressure point for their businesses, followed by rental costs (41.7%) and market competition (33.3%). Zooming into Hong Kong respondents, market competition was viewed as a more pressing challenge than rental costs, likely due to the increase in cross-border travel and change in consumption behaviours in recent years. In these circumstances, 38.7% would prioritise their investment in talent recruitment, followed by market promotion (38.1%) and personnel training (36.7%).About the GBAIThe GBAI is the first forward-looking quarterly survey in the market that looks at the business sentiment and synergistic effects in cities and industries across the GBA. It is compiled based on a survey of more than 1,000 companies in the GBA covering the manufacturing and trading, retail and wholesale, financial services, professional services and innovation and technology sectors. The index enables investors and businesses to better understand the current business climate, gauge future performance prospects and formulate their market strategies for the GBA.Related materialsStandard Chartered GBA Business Confidence Index Report: https://www.sc.com/hk/gba/gba-index-report/HKTDC Research: https://research.hktdc.com/en/article/MjMwNjM2MTgxMQReport and photos download: https://bit.ly/4u3izEMWing Chu, Deputy Director of Research, HKTDC (right), and Tommy Wu, Senior Economist, Greater China and North Asia, Standard Chartered (left), announced the latest GBA Business Confidence Index (GBAI) on 27 April 2026.Media enquiriesCorporate Affairs DepartmentStandard Chartered Bank (Hong Kong) Limited Flora Chiu Tel: (852) 3843 2285 Email: flora.chiu@sc.com   Communications & Public Affairs DepartmentHKTDC Christy LeeClayton Lauw Tel: (852) 2584 4369Tel: (852) 2584 4472Email: christy.wn.lee@hktdc.orgEmail: clayton.y.lauw@hktdc.orgAbout Standard CharteredWe are a leading international banking group, with a presence in 54 of the world’s most dynamic markets. Our purpose is to drive commerce and prosperity through our unique diversity, and our heritage and values are expressed in our brand promise, here for good.Standard Chartered PLC is listed on the London and Hong Kong stock exchanges.The history of Standard Chartered in Hong Kong dates back to 1859. It is currently one of the Hong Kong SAR’s three note-issuing banks. Standard Chartered incorporated its Hong Kong business on 1 July 2004, and now operates as a licensed bank in Hong Kong under the name of Standard Chartered Bank (Hong Kong) Limited, a wholly owned subsidiary of Standard Chartered PLC.For more stories and expert opinions please visit Insights at sc.com. Follow Standard Chartered on X, LinkedIn, Instagram and Facebook.About HKTDCThe Hong Kong Trade Development Council (HKTDC) celebrates its 60th anniversary this year. The HKTDC is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Follow us on  @hktdc and  LinkedIn Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

貿發局七大時尚創意及授權盛事 今日盛大揭幕

香港, 2026年4月27日 - (亞太商訊 via SeaPRwire.com) - 香港貿易發展局(香港貿發局)七大時尚生活產品及授權盛事今日揭幕,包括於今天至4月30日在灣仔香港會議展覽中心舉行的香港禮品及贈品展(禮品展)、香港時尚家品及家紡展(Home InStyle)、香港時裝節(Fashion InStyle),以及於亞洲國際博覽館舉行的香港國際印刷及包裝展(印包展)和香港奢侈品包裝展。而香港國際授權展(授權展)及亞洲授權業會議則由今天至4月29日在灣仔會展舉行。六項展覽共吸引來自超過30個國家及地區、約5,600家展商參與。香港貿發局總裁張淑芬表示:「香港一直是環球企業通往中國內地的主要門戶,擔當連接中國內地龐大市場與世界各地間的『超級聯繫人』和『超級增值人』的角色。香港憑藉穩固的優勢、完善的創新生態系統及知識產權基建,是企業拓展業務、實現創新發展,及將成果商業化的理想地。」創意禮品及家品薈萃 禮品展及Home InStyle成新品發佈平台禮品展與Home InStyle為買家帶來多元化禮品及家品選擇,產品涵蓋文化及創意、可持續發展、創新物料、樂齡科技等範疇。部份焦點內容集中於會展五樓展覽廳的全新Reimagine主題樓層,讓買家一站式掌握環球最新時尚家品及禮品方案,啟發業界想像未來產品的更多可能,帶來新視角及靈感。兩展亦吸引展商作發佈新產品平台。禮品展展商唯一冷熱水壺廠(展位:1E-D02)首次推出由香港插畫師 Pen So 與香港當代藝術家曹志豪設計的MINI20保溫杯盲盒。適逢其駱駝牌品牌與李小龍誕辰同樣迎來85周年,該展商亦推出另一聯乘保溫壺款式。Home InStyle展商百隆人工智能 (展位:5E-C20)首次展出防感染流動廁所,免安裝、無需用水,使用前後均無需重複消毒和接觸排泄物,更提供健康監測方案,將專業護理無縫融入現代家居。禮品展主打設計精品及訂製禮品禮品展於會展一樓展覽廳的卓越廊雲集超過100家本地及環球展商,主打高端及具設計特色的產品,涵蓋文具、家居用品及配備嶄新科技的智能精品。星光實業(展位:1C-G03)帶來紅 A「香港製造」迷你系列盲盒,以經典家品喚起1960至1990年代香港生活記憶。滙賢集團有限公司(展位:1C-E05)則展示為匹克球愛好者而設的 Napier Coded 背包,採用回收物料製成,結合運動與環保元素。Home InStyle引領家居新趨勢由創新科技署資助的樂齡科技及創新物料館(展位:5E-C20)設於Home InStyle,匯聚超過20家本地企業,展示樂齡科技產品、智能生活方案及創新物料家品。Scan Infinity Ltd帶來 TechFitX 智能運動訓練系統,透過切換組件及遊戲形式訓練, 讓長者輕鬆在家建立運動習慣。聯合國嶺南大學人道創新及科技中心展出 IntuCREW 智慧動力輔助解決方案,減輕照顧者推輪椅的體力負擔。其他產品包括聖諾盟 (Sinomax) 的仿生音波哄睡寶、德國寶 (German Pool) 的自然養生機,以及雅芳婷 (Afontane) 的自動清潔床上用品。創新物料方面,德塘瑞華國際股份有限公司展示以蓮花莖製成的可生物分解餐具及餐盒,以及蓮花纖維除臭貓砂; Editecture展出以回收塑膠瓶及瓶蓋碎片製成的 reEDIT 升級再造椅;Mush Composites則展示以農業副產品及菌絲體製成的生物基瓷磚,可應用於裝飾表面。Home InStyle另一焦點文創體驗區集合來自超過10個國家及地區、逾110家設計機構及文化品牌參與。當中包括印尼展商 PT MANAMU ANAIA SUMBA(展位:5E-C09A)帶來巴諾拉手鐲、捷克展商Izaak Reich Crystal s.r.o. (展位:5E-A14)展示超過150年歷史的手工玻璃、英國展商Block Design(展位:5E-C09B)的雙面造型玻璃花瓶、台灣展商Karari(展位:5E-A18)的線香器物、以及澳門展商(展位:5E-A16)的3D打印產品等。大會再度聯乘Pantone,以 2026 年度代表色「雲上舞白」為主題,打造不同家居陳列場景,幫助買家了解如何運用色彩配搭塑造時尚家居。Fashion InStyle展示環球時尚物料創新應用由香港貿發局主辦、香港特別行政區政府「文創產業發展處」資助的焦點展區NEXT@Fashion InStyle (NEXT)今年再度登場,展示時裝界如何通過創新物料引領產業變革、實踐永續發展。今年特別邀請菲律賓作為合作夥伴,並得到菲律賓駐香港貿易投資中心(PTIC-HK)及國際貿易展覽和代表團中心(CITEM)全力支持。而NEXT展區匯聚超過60家環球展商,覆蓋地域廣闊,當中有來自比利時的 Bloom Biotech (展位:3F-F09),展出微藻皮革,是首款採用可擴展綠色科技製的碳中和皮革替代品;而來自芬蘭的 Spinnova PLC(展位:3F-E04)展示以木材或廢棄纖維素製成的 SPINNOVA(R)新一代紡織纖維,適用於傳統紡織工藝,並可與棉纖維無縫混紡,為服裝及其他領域提供可擴展、可循環利用的紡織解決方案;而來自越南的 Thai Son S.P Co., Ltd.(展位:3F-F03)帶來多款織物,包括已有3000多年歷史的苧麻纖維不僅具有優異性能,更具有天然抗菌特性。NEXT展區還有來自香港、中國内地、泰國、印尼、冰島、瑞典、美國等地的展商展出各種創新物料。今年NEXT繼續邀請當代時尚品牌 Self-Portrait 創辦人兼創意總監 Han Chong 擔任項目顧問,帶領六組本地設計師及品牌組合,從八家物料供應商精選前瞻物料,傾力打造跨界企劃。今年更會首次利用香港及中國内地以外的物料進行設計,為時尚物料帶來新衝擊。如設計品牌WILSONKAKI將由法國供應商Chargeurs PCC提供的全球最輕H2物料、印尼供應商MYCL提供的菌絲皮革和香港供應商Texwinca提供的天然纖維糅合,透過層壓及黏合工藝,製作出兼具輕盈防護與自然觸感的日常單品。各組設計成品將在明天(4月28日)的時裝巡禮亮相。Fashion InStyle亦設有更多展區,包括設計師舞台、輔料及布料、時尚配飾、女裝、新娘禮服及晚裝、運動時尚等,展示各款成衣及配飾設計。Glory G International Limited(展位:3G-B31)展出「柔韌」系列輕質猄皮丹寧,打破牛仔褸沉重刻板印象;香港海源有限公司(展位:3G-F18)展出兼具裝飾性與實用性,可掛在手袋、鑰匙等物件作日常配搭的流蘇掛飾;來自烏茲別克的 Bibi Hanum(展位:3F-G29)則帶來具傳統特色的絲綢伊卡拼接裹身裙。印包展及奢侈品包裝展呈現綠色方案與高端工藝由貿發局和華港國際展覽有限公司主辦的印包展及香港奢侈品包裝展,展示創新、環保及高端印刷包裝方案。印包展展商環亞印刷包裝有限公司(展位:3-E01)推出的FSC無塑料纖維素膜包裝及FSC半透明紙袋,主打無塑膠及可回收,充分體現環保理念。寶紳國際香港有限公司(展位:3-E02)則帶來RFID(無線射頻識別)標籤,其內層以紙為原材料,兼顧永續設計。廣州市星啟元貿易有限公司 (展位:3-E11) 展示以農業廢料為原料的環保濕壓紙塑包裝,兼具實用性與環保價值。至於奢侈品包裝展,雅雋商務拓展(展位:3-A05)帶來立體旋轉音樂盒及復古留聲機禮盒,結合音樂播放、收納功能及高端包裝。美新隆(集團)有限公司(展位:3-A08)的紙燈籠花鳥罐採用一罐兩用設計,延長產品使用週期;亦帶來維港日夜光影禮盒,結合光影效果和收納功能,用於精緻食品包裝。授權展首設知識產權及電子商貿支援服務專區 拓展線上商機香港國際授權展匯聚來自香港、中國內地及亞洲各地超過 330 家參展商,展示超過 600 個品牌及知識產權項目,涵蓋藝術及文化、動畫與角色、品牌延伸、娛樂及體育授權等多個領域。展會首設知識產權及電子商貿支援服務專區,以配合特區政府積極提升港商在跨境電商平台競爭力的政策方向。專區匯聚多家電商平台、KOL、營銷及公關公司,包括電商平台Digitify Online Growth (展位:5G-E04)及營銷公司Matrix Promotion Limited (展位:5G-F01),支援品牌及知識產權項目把握電商發展帶來的新機遇。各大電商商會在展會期間舉辦包括搭建電商平台、透過電商平台「出海」和直播帶貨等相關的工作坊,協助業界掌握先機。授權展焦點 IP 包括 9GAG Limited 的 Potatoz(展位:5G-D20)、Toyzeroplus Limited 的 罐頭豬LULU(展位:5G-A24)、Yogurt Studio Ltd. 的 Café de Bollo(展位:5F-G20),以及來自中國內地的 乖巧寶寶(展位:5G-A22)、韓國的 LOTTY FRIENDS (展位:5F-G36)和泰國的 Warbie Yama(展位:5G-A51)等。由創意創業會主辦,香港特區政府文創產業發展處贊助的「香港設計授權‧支援計劃」在香港國際授權展續設「DLAB香港館」,雲集近40家展商,展示多個香港原創品牌及IP。大會亦再次與香港恒生大學、香港浸會大學及香港理工大學合作,並加入香港知專設計學院,舉辦香港授權新力量展區,展示本港新晉創意人才的創意設計。與展會同期舉行的亞洲授權業會議,邀請業界領袖探討多項市場焦點議題,當中今天會議邀請國際授權業協會行政總裁Maura Regan分享「2026年全球授權業趨勢展望」。適逢世界盃於今年舉行,會議亦邀請到國際足球協會(FIFA)高級授權經理Alessandro Villa及香港山成集團創辦人兼行政總監陳華俊分享成功體育授權後的商業策略。COVER株式會社執行副總裁兼銷售本部長毛延熙,將在明天探討虛擬 YouTubers (VTubers) 如何透過具策略性的社交媒體互動,與 Z 世代建立連結。研討會論壇探索市場新機遇為協助業界掌握最新發展趨勢,展會期間將舉辦約60場主題研討會、買家論壇、產品推廣及發佈會。內容聚焦銀髮經濟、市場趨勢、文化與創新,以及永續發展等熱門主題。其中,印包展及奢侈品包裝展其中一場研討會由貿發局與香港數碼印刷協會合辦,以「從指令到現實:生成式AI與數碼印刷的創意視覺革命」為題,分享生成式人工智能與數碼印刷如何推動創新轉型。禮品展與Home InStyle將舉行「循環再禮:永續家居與禮品設計的趨勢與突破」研討會,探討可持續設計的新方向。Fashion InStyle則會舉辦「文化融合×生活設計:『流行紋化』的超現實美」研討會,為業界帶來最新市場分析、創新思維及實踐策略。圖片下載:https://bit.ly/4vQE39E香港貿發局舉辦的香港禮品及贈品展、香港時尚家品及家紡展(Home InStyle)、香港時裝節(Fashion InStyle)、香港國際印刷及包裝展、香港奢侈品包裝展,以及香港國際授權展及亞洲授權業會議今天在香港會議展覽中心揭幕,六個展覽項目匯聚來自超過30個國家及地區、約5,600家展商。香港貿發局總裁張淑芬今早(4月27日)出席香港國際授權展與亞洲授權業會議開幕典禮,並為活動致開幕辭。(左起)文創產業發展處文創產業專員黎細明、亞洲旅遊交流中心主任張棟、香港貿發局總裁張淑芬、香港特區政府文化體育及旅遊局常任秘書長沈鳳君、泰國文化部Plan and Policy Analyst Expert Level Narathorn Parndee及國際授權業協會行政總裁Maura Regan共同主持開幕儀式。禮品展內的卓越廊雲集高端且具設計特色的禮品,涵蓋文具、家居用品及配備嶄新科技的智能精品。Home InStyle的樂齡科技及創新物料館,匯聚超過20家本地企業,展示樂齡科技產品、智能生活方案及多款可應用於家品及家紡市場的創新物料。文創體驗區集中展示環球文創家品,匯聚具有文化創意及獨特風格的設計師品牌。Fashion InStyle今年設有焦點展區NEXT@Fashion InStyle,項目合作夥伴菲律賓帶來超過25家展商展出當地時尚物料。NEXT@Fashion InStyle項目顧問Han Chong(中)帶領六組本地設計師及品牌打造多款選用精選環球創新物料的時裝設計。於印包展亮相的寶紳國際香港有限公司展示RFID(無線射頻識別)標籤,內層以紙為原材料,兼顧功能與永續設計。美新隆(集團)有限公司於奢侈品包裝展帶來維港日夜光影禮盒,結合光影效果和收納功能,用於精緻食品包裝。香港國際授權展今年首設知識產權及電子商貿支援服務專區。香港貿發局新聞中心:http://mediaroom.hktdc.com/tc香港禮品及贈品展:http://www.hktdc.com/event/hkgiftspremiumfair/tc香港時尚家品展 (Home InStyle):https://www.hktdc.com/event/homeinstyle/tc香港國際家用紡織品展 :www.hktdc.com/event/hkhometextilesfair/tc香港時裝節 (Fashion InStyle):www.hktdc.com/event/fashioninstyle/tc香港國際印刷及包裝展:https://www.hktdc.com/event/hkprintpackfair/tc香港國際授權展:https://www.hktdc.com/event/hklicensingshow/tc亞洲授權業會議:https://www.hktdc.com/event/hklicensingshow/tc/programme?category=all&date=all傳媒查詢新聞界如有查詢,請聯絡:香港時尚家品及家紡展(Home InStyle)、香港時裝節(Fashion InStyle)、香港禮品及贈品展、香港國際印刷及包裝展及香港奢侈品包裝展:Pandagon公關公司:  李彥煒電話:6083 5623電郵:pandagon.limited@gmail.com   香港貿發局傳訊及公共事務部:  劉茸電話:2584 4472電郵:clayton.y.lauw@hktdc.org香港國際授權展及亞洲授權業會議:言十公關公司:  劉碧思電話:6187 7786電郵:molisalau@raconteur.hk謝媛彰 電話:9742 7338電郵:betsytse@raconteur.hk   香港貿發局傳訊及公共事務部:  簡惠宜電話:2584 4055電郵:winnie.wy.kan@hktdc.org香港貿易發展局簡介香港貿易發展局(香港貿發局)今年慶祝成立60周年!成立於1966年,香港貿發局是負責促進、協助和發展香港貿易的法定機構。香港貿發局在世界各地設有超過50個辦事處,其中13個設於中國內地,致力推廣本港作為雙向環球投資及商業樞紐。 香港貿發局通過舉辦國際展覽會、會議及商貿考察團,為企業(尤其是中小企)開拓內地和環球市場的機遇。香港貿發局亦通過研究報告和數碼資訊平台,提供最新的市場分析和產品資訊。有關香港貿發局的其他資訊,請瀏覽www.hktdc.com/aboutus/tc。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

康哲藥業就已上市原研藥靜脈鐵劑莫諾菲和科莫非簽訂獨家商業化與供應協議

深圳, 2026年4月27日 - (亞太商訊 via SeaPRwire.com) - 康哲藥業控股有限公司(867.HK/8A8.SG)("康哲藥業")欣然宣佈,近期,康哲藥業通過其全資附屬公司與Pharmacosmos A/S就異麥芽糖酐鐵注射液("莫諾菲(R)")和右旋糖酐鐵注射液("科莫非(R)")簽訂獨家商業化與供應協議("協議")。根據協議,康哲藥業獲得了在中華人民共和國(就本協議而言,不含香港特別行政區、澳門特別行政區、臺灣地區)獨家商業化產品的權利,Pharmacosmos A/S繼續負責生產、供應產品。合作期限為協議約定的生效之日起十五年,到期前雙方可友好協商延長。本次合作的兩款靜脈鐵劑均為原研藥,已在中國獲批上市並納入國家醫保目錄。其中,莫諾菲(R)為獨家藥,是中國首款獲批上市的第三代靜脈鐵劑,具有更穩定的創新矩陣式納米結構,安全性更優[1],可一次足量補鐵,顯著減少輸注次數、更快提升血紅蛋白水平,提高臨床便捷性。另一款產品科莫非(R)為目前中國唯一被納入國家醫保目錄甲類,也是唯一被納入國家基本藥物目錄的靜脈鐵劑,臨床應用多年,其有效性與安全性已得到累積的臨床經驗和已發表數據的支持。上述兩款產品將形成覆蓋全渠道、全場景的靜脈補鐵產品矩陣,可滿足不同層級醫療機構、不同類型缺鐵性貧血患者的臨床需求,為患者提供更多元化、安全、高效的治療選擇。鐵缺乏症/缺鐵性貧血患者廣泛分佈於消化、心內、腎內、婦產、骨科等多個科室,均為康哲藥業的優勢專科領域,兩款產品的加入將與其現有在售產品的專家資源、學術推廣網絡高效協同,進一步強化康哲藥業在貧血治療領域的整體競爭力,並預期對其業績產生積極正面影響。關於莫諾菲(R)的更多信息莫諾菲(R)已於2021年1月30日獲批,用於治療口服鐵劑無效、無法口服補鐵或臨床需快速補鐵時的缺鐵狀況。2023年被納入《國家基本醫療保險、工傷保險和生育保險藥品目錄》(醫保目錄)乙類醫保。莫諾菲(R)由納米顆粒組成,其結構穩定、呈基質樣,由鐵原子層與短鏈線性异麥芽糖碳水化合物層交替構成。該結構可實現可控的鐵釋放,游離鐵含量更低,從而有助於形成良好的安全性特徵,包括較低的超敏反應和低磷血症風險。莫諾菲(R)可實現單次高劑量靜脈輸注給藥1000mg或更高劑量,而較早的療法(如蔗糖鐵)通常需要多次給藥,每次僅100至200 mg。因此莫諾菲(R)一次治療即可實現足量補鐵,减少輸注次數,減輕醫患負擔,並提升輸注能力。同時,其低磷血症風險較低,有助於避免骨折等併發症,並支持改善疲勞症狀(缺鐵性貧血關鍵症狀之一)。關於科莫非(R)的更多信息科莫非(R)為第二代低分子量右旋糖酐鐵注射液,於2003年在中國大陸獲批上市,用於無法口服鐵劑的缺鐵病人(如不耐受或口服鐵劑治療不滿意),同樣可實現單次大劑量足量補鐵。科莫非(R)憑藉多年臨床應用積累,其有效性與安全性已得到累積的臨床經驗和已發表數據的支持,其甲類醫保與基藥的雙重資質,支持其基層臨床補鐵的核心地位。關於鐵缺乏症和缺鐵性貧血鐵缺乏症(iron deficiency,ID)和缺鐵性貧血(iron deficiency anemia,IDA)是普遍影響兒童、停經前女性(尤其是孕婦)及老年人的全球性健康問題,可對多系統器官功能造成損害,引發生長發育遲緩、行為障礙、認知功能損傷、體能受損、圍產期及圍手術期併發症等一系列健康問題,亦會嚴重影響消化系統疾病、慢性腎臟疾病、心力衰竭及腫瘤等慢性疾病的預後[2]。超過10億人患有缺鐵性貧血[3],使其成為全球疾病負擔的主要因素之一[4]。中國第4次營養調查數據顯示,居民IDA患病率為20.1%[5],但醫患雙方重視程度不足,輕度貧血獲診治者不足20%,極重度貧血者亦僅50%獲診治,ID/IDA存在明顯診斷不及時及治療率偏低的情況[2]。補鐵為ID/IDA的常規治療方式,分為口服補鐵與靜脈補鐵,其中靜脈鐵劑是口服鐵劑不耐受、口服鐵劑療效不佳、臨床需快速補鐵、患者希望1-2次補足鐵量等情境下的重要手段[1,2,6]。但因對IDA重視不足、服藥依從性、住院時間、輸液便利性等條件限制,加上對靜脈鐵劑安全性的顧慮導致靜脈鐵劑使用較為保守。中國真實世界研究顯示,IDA患者蔗糖鐵使用總劑量均值為511mg,遠未達目標劑量1000mg[2]。臨床亟需安全性高、補鐵療效佳、可一次足量補鐵的靜脈鐵劑產品。莫諾菲(R)與科莫非(R)構建覆蓋全場景的靜脈補鐵產品矩陣,為缺鐵性貧血患者提供分層診療選擇。關於Pharmacosmos A/SPharmacosmos A/S為碳水化合物化學及缺鐵與缺鐵性貧血創新治療領域的全球領先企業。公司憑藉在碳水化合物化學與細胞週期生物學的深厚專業積累,致力於針對未被滿足的患者需求開發創新療法,重點關注鐵代謝及血液相關疾病。公司成立於1965年,總部位於丹麥,團隊由來自英國、愛爾蘭、北歐、德國、美國、加拿大及中國的700多名專家組成。憑藉優異的產品質量與臨床價值,核心鐵劑產品已於全球多個國家及地區獲批上市並廣泛應用,積累深厚技術實力與優質市場口碑。關於康哲藥業康哲藥業是一家鏈接醫藥創新與商業化,把控產品全生命週期管理的開放式平臺型企業,致力於提供有競爭力的產品和服務,滿足尚未滿足的醫療需求。康哲藥業專注於全球首創(FIC)及同類最優(BIC)的創新產品,並高效推進創新產品臨床研究開發和商業化進程,賦能科研成果向診療實踐的持續轉化,造福患者。康哲藥業聚焦專科領域,擁有被驗證的商業化能力,廣泛的渠道覆蓋和多疾病領域專家資源,核心在售產品已獲領先的學術與市場地位。康哲藥業圍繞優勢專科領域不斷縱深發展,以鞏固心腎代謝/消化/眼科/皮膚健康業務競爭力,帶來專科規模效率,其中皮膚健康業務(德鎂醫藥)已成為其細分領域的龍頭企業,並擬於聯交所獨立上市。同時,康哲藥業持續推動研產銷全產業鏈在東南亞及中東區域運營發展,以獲取新興市場的增量,助力集團實現高質量可持續發展。參考文獻/資料1. 中國藥理學會藥源性疾病學專業委員會. 廣東省藥學會. 靜脈鐵劑的臨床應用和藥學監護專家共識(2024)[J]. 藥物不良反應雜誌, 2025, 27(3): 129-141. DOI: 10.3760/cma.j.cn114015⁃20240929⁃000702. 廖敏婧, 張連生. 鐵缺乏及缺鐵性貧血規範化診治[J]. 中華內科雜誌, 2023, 62(6): 722-727. DOI: 10.3760/cma.j.cn112138-20230210-00074.3. Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019 (GBD 2019) Results. Seattle, United States: Institute for Health Metrics and Evaluation (IHME); 2020. Available from http://ghdx.healthdata.org/gbd-results-tool.4. Pasricha SR, Tye-Din J, Muckenthaler MU, Swinkels DW. Iron deficiency. Lancet. 2021 Jan 16;397(10270):233-248.5. 李莉娟, 張連生. 缺鐵性貧血規範化診治的若干問題[J]. 中華醫學雜誌, 2021, 101(40): 3266-3270. DOI: 10.3760/cma.j.cn112137-20210609-01319.6. 中華醫學會血液學分會紅細胞疾病(貧血)學組. 鐵缺乏症和缺鐵性貧血診治和預防的多學科專家共識(2022年版)[J]. 中華醫學雜誌, 2022, 102(41): 3246-3256. DOI: 10.3760/cma. j.cn112137-20220621-01361.康哲藥業免責與前瞻性聲明本新聞無意向您做任何產品的推廣,非廣告用途。本新聞不對任何藥品和醫療器械和/或適應症作推薦。若您想了解具體疾病診療信息,請遵從醫生或其他醫療衛生專業人士的意見或指導。醫療衛生專業人士作出的任何與治療有關的決定應根據患者的具體情況並遵照藥品說明書。由康哲藥業編制的此新聞不構成購買或認購任何證券的任何要約或邀請,不形成任何合約或任何其他約束性承諾的依據或加以依賴。本新聞由康哲藥業根據其認為可靠之資料及數據編制,但康哲藥業並無進行任何說明或保證、明述或暗示,或其他表述,對本新聞內容的真實性、準確性、完整性、公平性及合理性不應加以依賴。本新聞中討論的若干事宜可能包含涉及康哲藥業的市場機會及業務前景的陳述,該等陳述分別或統稱為前瞻性聲明。該等前瞻性聲明並非對未來表現的保證,存在已知及未知的風險、不明朗性及難以預知的假設。康哲藥業並不採納本新聞包含的第三方所做的任何前瞻性聲明及預測,康哲藥業對該等第三方聲明及預測不承擔責任。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

CMS (867.HK/8A8.SG) Signed An Exclusive Commercialization and Supply Agreement for Marketed Originator Intravenous Iron Products Monofer(R) and Cosmofer(R)

SHENZHEN, Apr 27, 2026 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that, the Group through its wholly-owned subsidiary entered into an exclusive commercialization and supply agreement (the “Agreement”) with Pharmacosmos A/S for Iron Isomaltoside Injection (“Monofer®”) and Iron Dextran Injection (“Cosmofer®”) recently. In accordance with the Agreement, the Group has obtained an exclusive right to commercialize the products in the People’s Republic of China (for the purpose of this Agreement, excluding the Hong Kong Special Administrative Region, the Macau Special Administrative Region and Taiwan region). Pharmacosmos A/S will continue to manufacture and supply the products. The cooperation term shall be fifteen years from the effective date stipulated in the Agreement, which may be extended upon mutual agreement between the parties prior to expiry.The two intravenous iron therapies under this cooperation are both originator products that have been approved for marketing in China and included in the China’s National Reimbursement Drug List (NRDL). Among them, Monofer® is an exclusive drug and the first third-generation intravenous iron therapy approved for marketing in China. It features an innovative and more stable matrix-like nanostructure and provides a superior safety profile[1]. Its single-dose full iron replenishment significantly reduces the number of infusions, enables faster improvement in hemoglobin levels and enhances clinical convenience. Another product, Cosmofer®, is currently the only intravenous iron therapy included in Category A of the NRDL and also the only one included in the National Essential Medicines List (NEML). With many years of accumulated clinical use, its efficacy and safety have been supported by accumulated clinical experience and published data.The above two products will form a comprehensive intravenous iron product portfolio covering all channels and treatment scenarios, which can support meeting the clinical needs of different levels of healthcare institutions and different types of iron deficiency anemia (IDA) patients, providing more diversified, safe and effective treatment options for patients. Patients with iron deficiency (ID) and IDA are widely distributed across multiple clinical departments, including gastroenterology, cardiology, nephrology, obstetrics and gynecology, and orthopedics, which are all key specialty areas of the Group. The addition of the two products will generate efficient synergies with the Group’s existing marketed products in expert resources and academic promotion network, further strengthening the Group’s overall competitiveness in the field of anemia treatment, and is expected to have a positive impact on the Group’s performance.More information about Monofer®Monofer® was approved on 30 January 2021 for the treatment of iron deficiency in patients where oral iron preparations are ineffective, cannot be used, or where there is a clinical need for rapid iron supplementation. In 2023, Monofer® was included in the NRDL as a Category B reimbursable drug. Monofer® consists of nanoparticles with a stable, matrix-like structure composed of interchanging layers of iron atoms and short, linear isomaltose carbohydrates. This structure enables controlled iron release with low levels of labile iron, contributing to a favourable safety profile, including a low risk of hypersensitivity reactions and hypophosphatemia. Monofer® can be administered as a high-dose infusion of 1,000 mg or more in a single visit, whereas older therapies such as iron sucrose typically require repeated administrations of 100 to 200 mg. This enables full iron repletion in one treatment, reducing the need for multiple infusions, lowering the burden on patients and healthcare systems, and increasing infusion capacity. At the same time, the low risk of hypophosphatemia helps avoid complications such as fractures and supports recovery from fatigue, a key symptom of iron deficiency anaemia.More information about Cosmofer®Cosmofer® is a second-generation low-molecular-weight iron dextran injection. It was approved for marketing in Mainland China in 2003 and is indicated for patients with iron deficiency who cannot take oral iron preparations (such as those who are intolerant to oral iron or have unsatisfactory therapeutic outcomes). Cosmofer® also allows single-dose high-dose iron repletion. With many years of accumulated clinical use, its efficacy and safety have been supported by accumulated clinical experience and published data. Its dual status as a Category A NRDL-listed product and NEML supports its core role in iron supplementation in primary healthcare settings.About Iron Deficiency and Iron Deficiency AnemiaID and IDA are global health issues that commonly affect children, premenopausal women (particularly pregnant women) and the elderly. These conditions may impair the function of multiple organ systems, leading to a series of health problems such as growth retardation, behavioral disorders, cognitive impairment, reduced physical capacity, and peri-natal and peri-operative complications. They also significantly affect the prognosis of chronic diseases such as gastrointestinal diseases, chronic kidney disease, heart failure and tumors[2]. More than 1 billion people live with iron deficiency anaemia[3], making it one of the leading contributors to the global burden of disease[4]. Data from the Fourth National Nutrition Survey in China indicate that the prevalence of IDA among Chinese residents is 20.1%[5]. However, both patients and healthcare professionals have insufficient awareness of the disease. Less than 20% of patients with mild anemia receive diagnosis and treatment, while only about 50% of patients with severe anemia receive appropriate diagnosis and treatment[2]. This indicates significant underdiagnosis and undertreatment of ID/IDA. Iron supplementation is the standard treatment for ID/IDA and includes oral iron therapy and intravenous iron therapy. Intravenous iron therapy is an important option for patients who cannot tolerate oral iron, have inadequate response to oral therapy, require rapid iron repletion, or prefer full iron supplementation within one to two administrations[1,2,6]. However, due to insufficient awareness of IDA, patient adherence issues, hospitalization constraints, infusion convenience, and safety concerns regarding intravenous iron therapies, the clinical use of intravenous iron in China remains relatively conservative. A Chinese real-world study shows that the average total dose of iron sucrose used in IDA patients was approximately 511 mg, which was significantly lower than the target dose of 1,000 mg[2]. There is therefore a significant clinical need for intravenous iron therapies that offer high safety, strong demonstrated efficacy and single-dose full iron repletion. Monofer® and Cosmofer® together establish a comprehensive intravenous iron product portfolio covering multiple treatment scenarios, providing tiered treatment options for patients with iron deficiency anemia.About Pharmacosmos A/SPharmacosmos A/S is a global leader in carbohydrate chemistry and innovative treatments for iron deficiency and iron deficiency anemia. Leveraging its deep expertise in carbohydrate chemistry and cell cycle biology, the company is committed to developing innovative therapies to address unmet patient needs, with a particular focus on iron metabolism and hematology-related diseases. Pharmacosmos A/S was founded in 1965 and is headquartered in Denmark, and employs more than 700 specialists from the United Kingdom, Ireland, the Nordic countries, Germany, the United States, Canada and China. With excellent product quality and strong clinical value, its core iron therapy products have been approved and widely used in multiple countries and regions worldwide, establishing strong technological capabilities and a solid market reputation.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardiovascular-kidney-metabolic/gastroenterology/ophthalmology/skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.Reference:1. Chinese Pharmacological Society Professional Committee of Drug‑induced Diseases, Guangdong Pharmaceutical Association. Expert consensus of clinical application and pharmaceutical care for intravenous iron agents (2024) [J]. Adverse Drug Reactions Journal, 2025, 27(3): 129-141. DOI: 10.3760/cma.j.cn114015⁃20240929⁃000702. Liao Minjing, Zhang Liansheng. Standardized diagnosis and treatment of iron deficiency and iron‑deficiency anemia [J]. Chinese Journal of Internal Medicine, 2023, 62(6): 722-727. DOI: 10.3760/cma.j.cn112138-20230210-00074.3. Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019 (GBD 2019) Results. Seattle, United States: Institute for Health Metrics and Evaluation (IHME); 2020. Available from http://ghdx.healthdata.org/gbd-results-tool.4. Pasricha SR, Tye-Din J, Muckenthaler MU, Swinkels DW. Iron deficiency. Lancet. 2021 Jan 16;397(10270):233-248.5. Li Lijuan, Zhang Liansheng. Considerations on the standardized diagnosis and treatment of iron‑deficiency anemia [J]. National Medical Journal of China, 2021, 101(40): 3266-3270. DOI: 10.3760/cma.j.cn112137-20210609-01319.6. Red Blood Cell Disease (Anemia) Group, Chinese Society of Hematology, Chinese Medical Association. Multidisciplinary expert consensus on the diagnosis, treatment and prevention of iron deficiency and iron deficiency anemia (2022 edition) [J]. National Medical Journal of China, 2022, 102(41): 3246-3256. DOI: 10.3760/cma. j.cn112137-20220621-01361.CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Kincora Investor Webinar Invitation

Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - April 27, 2026) - Copper-gold explorer and hybrid project generator Kincora Copper Limited (ASX: KCC) (TSXV: KCC) (Kincora or the Company) is pleased to announce that it will be holding an Investor Webinar Presentation and Discussion on the afternoon of Tuesday April 28th Pacific Standard Time (PST) and morning of Wednesday 29th Australian Eastern Standard Time (AEST).President & Chief Executive Officer, Mr Sam Spring, will update the market on recent and upcoming drill programs, exploration activities and corporate developments across the project portfolio.Both Kincora shareholders and interested investors are invited to attend the webinar and participate in the accompanying Q&A session.Kincora Copper Investor Webinar Details: Canada(Vancouver)US(Dallas)Australia(East Coast)Date28-Apr-202628-Apr-202629-Apr-2026Time4.00PM PST6.00PM CT9.00AM AEST Please note: Registration is required to attend this Zoom format investor webinar.Please register in advance for the Zoom webinar using the following link:https://us02web.zoom.us/webinar/register/WN_IE079ntuTbmoCUiWm6_O5QAfter registering, you will receive a confirmation email containing information about joining the webinar.Questions can be submitted in advance of the webinar to Julia Maguire of The Capital Network via the following email address: julia@thecapitalnetwork.com.auA replay of the webinar will be available on Kincora's website on the following page:https://kincoracopper.com/interviews/About Kincora: Kincora Copper Limited (ASX: KCC) (TSXV: KCC) is an emerging Australia-focused gold-copper explorer with a hybrid project generator strategy.The Company is successfully proving up the prospectivity of its extensive project portfolio, which includes multiple district-scale landholdings and scalable drill ready targets. These assets are located in Australia's Lachlan Fold Belt and Mongolia's Southern Gobi, two of the globe's leading porphyry belts, and the historical Condobolin mining field within the Cobar basin in NSW.The Company has already unlocked over $100 million of potential partner funding for multiple earlier stage and/or non-core porphyry projects. These initial deals have supported over 18,000 metres of drilling and over A$9m of partner funded exploration since late 2024, with management fees and exploration ramping up.Partner discussions are ongoing for its remaining 100% owned flagship projects that are all situated within existing porphyry camps containing over 20-million-ounce gold equivalent resource inventory.By having a significant portfolio of partner funded large porphyry projects, and a very focused capital efficient programs at the Condobolin and other sole funded projects, the Company is seeking to position Kincora as a leading institutional grade explorer in the public Australian and Canadian markets, and the leading project generator on the ASX.The Company's website is: www.kincoracopper.comThis announcement has been authorised for release by the Board of Kincora Copper Limited (ARBN 645 457 763)For further information please contact:Sam Spring, President and Chief Executive Officersam.spring@kincoracopper.com or +61431 329 345 Laurie Thomas, Strategic Advisor laurie.thomas@kincoracopper.com or +1306 341 3826 Media contactJulia Maguire, Managing Director, The Capital Networkjulia@thecapitalnetwork.com.au or +61 2 7257 7338Executive office Subsidiary office Australia 400 - 837 West Hastings Street C/- JM Corporate ServicesVancouver, BC V6C 3N6, Canada Level 6, 350 Collins StreetTel: 1.604.283.1722 Melbourne, VIC, Australia 3000 Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) or the Australian Securities Exchange accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/294246 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com